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Summary 
 
p53 is a tumour suppressor protein involved in maintenance of genomic stability of the cell. 
Primarily, p53 protects the cell from malignant transformation through cell cycle arrest and 
apoptosis. While mutations in p53 occur in less than 10% of acute myeloid leukaemia (AML), 
over-expression of the main negative regulator of p53, MDM2, is frequently observed, 
representing a mechanism of p53 silencing. Furthermore, aberrant recruitment of histone 
deacetylases (HDACs) is also seen in AML, leading to block of myeloid differentiation. 
HDACs deacetylate histones and transcription factors such as p53, leading to increased 
chromatin compaction, representing an additional means for silencing p53 activity.  
 
In this study, we have evaluated the effect of a combination of two drugs affecting the 
regulation of p53 in AML cells; nutlin-3 and valproic acid (VPA). Nutlin-3 is a non-genotoxic 
MDM2 antagonist, which specifically disrupts the MDM2-p53 interaction by binding to the 
p53 specific site on MDM2. This leads to activation of p53 and the p53 pathway in cancer 
cells with wild type p53, subsequently inhibiting tumour growth. VPA is a well-tolerated non-
genotoxic HDAC inhibitor inhibiting deacetylation of chromatin and transcription factors 
such as p53, and has been found to show an anti-leukemic effect in AML patients. These two 
therapeutic compounds both indirectly activate p53, thereby presenting a combinational non-
genotoxic p53 activation strategy, in contrast to conventional chemotherapy and bone marrow 
transplantation.  
 
Nutlin-3 and VPA in combination was found to show a synergistic effect in vitro in an AML 
cell line expressing wild type p53 (MOLM-13). An imageable MOLM-13 AML xenograft 
mouse model was then successfully developed to enable evaluation of the combinational 
therapeutic strategy in vivo using optical imaging. Nutlin-3 and VPA combined was found to 
delay AML development and increase survival in vivo. These pilot results suggests the p53 
activating strategy as a valuable concept in the treatment of AML, and should indeed be 
further evaluated. 
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1 Introduction 
1.1 Acute myeloid leukaemia 
1.1.1 Biology and classification of AML 
Acute myeloid leukaemia (AML) is a collective term for a number of related malignant 
disorders of the myeloid progenitor lineage (Fig. 1.1A). In Norway, approximately 100 
patients are diagnosed with AML each year [1], with incidence increasing with age (Fig. 
1.1B) and an overall four-year survival of 43 % [2]. Median age at diagnosis is 64 years, and 
survival in the elderly rarely exceeds two years despite of treatment [3, 4]. 
 
Figure 1.1 Development 
and epidemiology of AML. 
(A) The hierarchical 
development of 
haematopoietic cells, 
initiating from 
haematopoietic stem cells 
(HSC) through common 
lymphoid progenitors (CLP) 
and common myeloid 
progenitors (CMP), 
subsequently developing 
functional differentiated 
lymphoid and myeloid cells, 
respectively. Development of 
AML occurs at some stage in 
the myeloid progenitor 
lineage (encircled). (B) 
Incidence of AML increases 
drastically with age in the 
elderly population (aged > 
60). Unfortunately, this 
group does not tolerate the 
current standard AML 
therapy, and few alternatives 
are available. Figures from 
[5, 6].  
 
 
 
AML is characterized by increased proliferation of myeloid progenitor cells in the bone 
marrow and differentiation block. Resulting accumulation of myeloid cells in the marrow 
eventually leads to cytopenia due to leucopoenia, anaemia and thrombocytopenia. 
Subsequently, the clinical signs and symptoms of AML arise, such as fever or infections, 
fatigue and haemorrhage, respectively [6-8]. Other symptoms may occur upon infiltration of 
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tissues such as liver, spleen, lymph nodes and the central nervous system (CNS) [6, 7]. Such 
symptoms include splenomegaly, hepatomegaly, lymph node enlargement, headaches, and 
blurred vision and balance difficulties. 
 
Diagnosis of AML has until recently been based on the French-American-British (FAB) 
classification; i.e. morphology showing > 30% blasts in the bone marrow being diagnosed as 
AML and subgroups divided into groups from M0-M8 based on cytogenetics. The World 
Health Organization (WHO) has now changed the classification of these subgroups to a 
morphology showing > 20% blasts, cytogenetic profile and distinctive clinical signs [1, 9]. 
Disease prognosis depends on age, genetic mutations or overexpression of specific genes, 
presence of multidrug resistance mechanisms such as the multidrug resistance (MDR) 1 gene, 
and the karyotype of the leukemic cells. Cytogenetic analysis and immunophenotyping are 
methods used as both diagnostic and prognostic tools to indicate the prognostic risk of 
patients; favourable, intermediate or poor [10].  
 
1.1.2 AML therapy 
Chemotherapy is the standardized therapy of AML of today, with mean survival of AML 
patients without chemotherapeutic intervention only 1-2 months [11]. Complete remission 
(CR) is characterized by < 5% blasts in the bone marrow, and is a condition for long-time 
survival or full recovery after primary AML [1, 10]. The current standard clinical therapy 
results in approximately 50-75% CR of AML patients, however only 20-30% achieve long-
term disease-free survival [10].  
 
There has been little change in therapy regimen of AML the last decades. Standard induction 
therapy consists of a of an anthracycline antibiotic, such as daunorubicin, idarubicin, 
doxorubicin or mixantrone in combination with cytarabine (Ara-C) [7, 10]. In Norway the 
standard induction regimen is the 7 + 3 combination, consisting of the cytidine analogue 
cytarabine  (Ara-C) at 200 mg/m2 body-surface administered over 24 hours as continuous 
infusion for 7 days, combined with either daunorubicin at 50 mg/m2 body-surface or 
idarubicin at 12 mg/m2, administered in bolus doses daily for three days [1].  
 
The antracycline antibiotics are a class of DNA intercalating drugs which are known to inhibit 
topoisomerase II and generate toxic free radicals [12], their mechanism is, however, not yet 
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fully understood. The response includes activation of the p53 pathway and subsequent cell 
cycle arrest or apoptosis [13]. These agents are mostly active in the G2/M phase of the cell 
cycle, however, are not tumour specific, leading to their main adverse effects such as bone 
marrow depression, gastro-intestinal (GI) disturbances and cardiac toxicity [12, 14]. The 
cytidine analogues are antimetabolites that must penetrate the cell before being converted to 
the active metabolite, are then further incorporated into DNA, and subsequently inhibit the 
replication and repairing activity of DNA polymerase [12]. The toxicity profile is very similar 
to anthracyclines with bone marrow suppression and GI disturbances, however agents are 
mostly active in S-phase [12, 15]. 
 
Treatment of patients suffering from acute promyelocytic leukaemia (APL; FAB M3) with the 
promyelocytic leukaemia-retinoic acid receptor α (PML-RARα) fusion gene is further 
supplemented with all-trans retinoic acid (ATRA), and is an example of a successful specific 
targeted therapy [1, 16]. ATRA is a differentiation agent specifically inducing terminal 
differentiation of promyelocytes by reactivating RAR-target genes suppressed by the PML-
RARα fusion protein, additionally to degrade the PML-RAR fusion protein [17-19]. 
 
Postremission therapy is given to prevent relapse and includes intensive consolidation 
chemotherapy of high-dose cytarabine, allogenic or autologous stem cell transplantation or 
low-dose maintenance therapy [1, 10]. However, elderly patients (aged over 60) have a high 
risk of therapy related toxicity because of lower tolerance to this intensive consolidation 
therapy. A higher frequency of karyotype indicating poor prognosis and MDR1 gene 
expression also leave this group more resistant to chemotherapy. These patients show a high 
incidence of relapse, with overall survival rate less than 10 %.  Therapy for this group is very 
individual, based on pre-existing co-morbidities, and often consists of supportive and 
palliative treatment [1, 8, 10]. Considering the median age of AML patients of 64 years and 
the above mentioned poor prognosis, there is a need for development of new specific targeted 
therapeutics of AML that show low toxicity. 
 
1.1.3 Specific targeted therapy  
Increasing attention has been drawn to the use of specific targeted therapy as a strategy to 
avoid genotoxicity of standard chemotherapy in AML. The combination of valproic acid 
(VPA) and ATRA has been elucidated in clinical trials with AML patients showing disease 
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stabilization in a subset of patients [20-22]. VPA is believed to increase the sensitivity of 
AML cells towards ATRA by inhibiting abnormal recruitment of histone deacetylases 
(HDACs), leading to an increase in ATRA induced differentiation due to expression of 
retinoid responsive genes [23, 24]. ATRA itself shows some induction of histone acetylation, 
however a lower effect than compared to VPA [24]. Further, VPA and ATRA have been 
combined with theophylline, the latter as an agent to increase intracellular cyclic adenosine 
monophosphate (cAMP), increasing the differentiation process [20]. This combination 
treatment with ATRA, VPA and theophylline therapy was found to be disease stabilizing for a 
subset of non-APL AML patients not suitable for intensive chemotherapy. One out of eleven 
patients had a complete remission [20]. In our department, there is at present an ongoing 
clinical trial with VPA in combination with ATRA and low dose cytarabine for treatment of 
AML patients aged > 60 and/or unsuitable for intensive chemotherapy. Valproic acid is 
administered continuously in dosages required to reach therapeutic serum levels of at least 
300-600 micromolar (µM), initially as intravenous bolus doses, thereafter as oral treatment. 
Additionally, 21.5 mg/m2 of ATRA administered orally twice daily for two weeks initiated 
seven days after VPA, and 10 mg/m2 cytarabine administered subcutaneously once daily for 
ten days, initiated two weeks after VPA.  
 
The above mentioned strategies for alternative treatment of AML shows that large effort is 
being made to find a suitable therapy for AML patients not tolerating the intensive standard 
therapy of today. Moreover, that specifically targeting known AML aberrations is being 
highly valued in search for new therapeutic alternatives. The high number of genetic 
aberrations identified in AML suggests a variety of additional potential therapeutic targets, 
and such novel specific targeted strategies are currently under investigation.   
 
1.1.4 The molecular pathogenesis of AML and potential therapeutic targets 
The pathogenesis of AML involves a wide range of molecular alterations that can lead to 
malignant cell transformation. Inappropriate proliferation, differentiation blockade, indefinite 
self-renewal and escape from programmed cell death are examples of such. Additionally, loss 
of cell cycle control and DNA repair, genomic instability, and multi-organ dissemination of 
malignant cells are processes that may disrupt normal regulatory networks. This may further 
lead to onset and progression of AML. The wide variation of molecular alterations in AML 
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may provide potential subtype specific therapeutic targets, and heavy research is going on to 
identify targets and find potential agents [25].  
 
Mutations in proteins involved in proliferative signalling pathways may lead to autonomous 
cell proliferation. E.g. activating mutations in the tyrosine kinase fms-like tyrosine kinase 3 
(FLT3) results in constitutive activation and subsequent proliferation in approximately 30 % 
of AML patients and is associated with poor prognosis independent of age [17, 25, 26]. As a 
consequence, search for FLT3-selective inhibitors has been highly appreciated in AML 
research, and several such inhibitors are in phase II trials [25, 26], the PKC412 is a FLT3 
inhibitor in phase III trial [25]. Loss of differentiation and ability of self-renewal in AML 
cells may result from disruption of transcription factors by chromosomal translocation or 
point mutations. The already mentioned PML-RARα fusion is an example of such, where use 
of the specific targeting ATRA has drastically improved the prognosis for the patient group 
showing this genetic alteration [16-19]. 
 
Evasion of apoptosis and loss of cell cycle control may be a result of overexpression of the 
pro-survival protein Bcl-2, deletion or mutation of the tumour suppressor retinoblastoma (Rb), 
or dysfunction or mutation of the tumour suppressor p53. Mutations in the gene encoding p53 
(TP53) is found in over 50 % of human cancers, however in less than 10 % of AML cases [27, 
28]. Adverse response to chemotherapy in AML patients has been correlated with mutations 
in p53, such mutations have further been positively correlated with increasing age [29]. 
Despite the low frequency of p53 mutations,  dysfunction of p53 in AML may occur by other 
mechanisms, such as by suppression of its positive regulator, the alternative reading frame 
(ARF) protein, overexpression of its negative regulator murine double minute 2 (MDM2), 
aberrant recruitment of HDACs or functional disruption of the nucleophosmin protein 1 
(NPM1, nucleolar phosphoprotein B23, numatrin) [17]. Mutations in the gene encoding the 
p53 stabilizing NPM1 protein are among the most frequent genetic abnormalities in AML; 
approximately 35 % of adult AML patients have mutations within the NPM1 gene, in AML 
cases with normal karyotype, 50 – 60 % have such mutations [30].  
 
The above mentioned AML characteristics suggest a strategy for silencing of p53 activity 
even in the absence of p53 mutations. Many of the specific targeted therapies investigated as 
alternative AML therapy are specific for AML subtypes, i.e. may be efficient for specific 
patient groups showing the respective molecular alterations. However, p53 is known to be 
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wild type in 90 % of AML and therefore potentially would provide a promising target for the 
majority of AML patients. By specifically targeting p53 silencing strategies, p53 would be 
allowed to play its central role in cell cycle control, and subsequently prevent further 
proliferation of AML cells and development of AML. 
 
1.2 Biology and function of the tumour suppressor protein p53  
The tumour suppressor protein p53, “the Guardian of the Genome” [31], is involved in 
maintaining genomic stability of the cell through cell cycle arrest and apoptosis, thereby 
protecting the cell from malignant transformation. Activation occurs as a response to stress 
signals such as DNA damage, oncogene activation, and chemotherapy, eventually leading 
either to cell cycle arrest or apoptosis [32]. The level of p53 is controlled by proteosomal 
degradation, mainly mediated by the protein MDM2 [33]. Upon stress signalling, the short 
half-lived p53 protein is stabilized and activated, resulting in higher levels of p53. When 
activated, p53 as transcription factor enhances the rate of transcription of a number of genes 
involved in cell-cycle inhibition, apoptosis, genetic stability and inhibition of blood-vessel 
formation [34]. The p21 gene is an example of a gene transcribed by p53 encoding a protein 
p21 involved in cell-cycle arrest, the Bax gene encodes a pro-apoptotic protein in the Bcl-2 
family. In addition, p53 is a transcription factor of one of its own negative regulators, MDM2, 
resulting in a negative feedback loop [32], controlling its strict regulation during cell cycle.  
 
1.2.1 Regulation of p53 
Activation of p53 involves interruption of the p53-MDM2 interaction (Fig. 1.2), in addition to 
stabilizing modifications of p53, such as acetylation by histone acetyltransferases (HATs) and 
phosphorylation by kinases [35]. Sumoylation and methylation of p53 have also been 
included as stabilizing and activating modifications of p53 [36, 37]. Subsequently, p53 
accumulates, p53 binding to DNA is enhanced and the affinity of MDM2 for p53 is reduced 
[32]. Other modifications may reduce the activity of p53, and even mark it for degradation. 
HDACs deacetylate p53 and phosphatases dephosphorylate, both leading to destabilization of 
p53  and subsequent decrease in p53 activity [35]. Ubiquitination of p53 by ubiquitin ligases 
such as MDM2 marks it for proteosomal degradation, but also ubiquitination by the ubiquitin 
ligases Pirh-2, Cop-1 and CARPs, and neddylation of p53 by MDM2, has been found to 
inhibit p53 transcription activity [35, 38, 39]. A simplification of the complex p53 regulation 
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network is shown in Fig. 1.2. The mechanism by which regulation of p53 activity occurs is 
through a large network of autoregulatory feedback loops. p53 is part of at least 10 feedback 
loops; seven negative and three positive [34]. Negative feedback loops downregulate p53 
activity and involves the ubiquitin ligases MDM2, Cop-1,  Pirh-2 and CARPs [39], in 
addition to p73 delta N, cyclin G, Wip-1 and Siah-1. Positive feedback loops involves PTEN-
AKT, p19 ARF and Rb. As can be interpreted from this complex regulation network of p53, 
alterations in any of these regulators will influence p53 activity. As the majority of the 
feedback loops are negatively regulating p53, the probability is high for such an alteration to 
negatively regulate p53 activity, potentially leading to loss of cell cycle control and cancer. 
 
 
 
Figure 1.2 Activation and regulation of the tumour suppressor p53. Upon cellular stress such as DNA 
damage, p53 is released from MDM2 mediated suppression by stabilizing and activating modifications as 
acetylation and phosphorylation. In complex with a transcriptional machinery consisting of various proteins, p53 
then acts as transcription factor for genes encoding proteins involved in growth arrest, cellular senescence and 
apoptosis. Upon completion of stress-response, p53 activity is again reduced through deacetylation by the 
HDACs HDAC I and Sir2 (see section 1.4 for more details), allowing interaction with MDM2 leading to 
inhibition of p53 transcription activity, nuclear export and ubiquitination of p53 followed by proteosomal 
degradation (see section 1.3 for more details). Aberrant recruitment or overexpression of HDACs or MDM2 may 
lead to silencing of p53 activity, and may in such cases be possible targets for p53 activating therapy. Ac, acetyl; 
P, phosphate; Ub, ubiquitin. 
 
1.2.2 The role of p53 in cancer and AML 
Considering the pivotal role of p53 as cellular gatekeeper for growth and division, it is not 
surprising that mutations in the gene encoding p53 (TP53) has been found in over 50 % of 
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human cancers [40]. However, such mutations are found in less than 10 % of AML cases [27, 
28]. Nevertheless, AML has various different genetic alterations, whereof some may 
contribute to silence p53 activity. Examples of such are overexpression of MDM2 and 
aberrant recruitment of HDACs. Silencing of p53 activity may provide AML cells with a 
growth advantage, and continuous cell proliferation may occur until more oncogenic events 
occur. As MDM2, the main negative regulator of p53, has been found frequently 
overexpressed in AML [41-44] it suggests a potential therapeutic target for p53 activation.    
 
1.3 The biology of MDM2 and function in AML 
Human MDM2 (hdm2) is a 491-amino acid long phosphoprotein, which interacts with and 
inhibits p53 [33].  Additionally, MDM2 interacts with other proteins, such as the E2F1 
transcription factor, MDM2’s own negative regulator p14ARF and the tumour suppressor  
protein retinoblastoma (Rb) [33, 45].  
 
MDM2 is able to repress p53 by three mechanisms [33, 45, 46], (1) interaction of its amino 
terminal with the amino terminal transactivation domain of p53 - directly blocking p53 
transcriptional activity, (2) the MDM2 E3 ligase domain ubiquitinates p53 and marks p53 for 
proteosomal degradation, and (3) transportation of p53 from the nucleus to cytoplasm, thereby 
obstructing it’s transcriptional activity. p53 binds to MDM2 in a hydrophobic cleft formed by 
the amino terminal of MDM2, this binding has been found to require only three amino 
residues of the p53 transactivation domain; Phe19, Trp23 and Leu26, as shown in Fig. 1.3 
[47]. 
 
Figure 1.3 The p53-MDM2 interaction. 
The aminoterminal of p53 (deep blue) in the 
p53 binding groove of MDM2 (orange), with 
the three crucial amino acid residues Phe19, 
Trp23 and Leu26 (highlighted in yellow) 
pointing towards the bottom of the groove 
due to hydrogen bonding. Modified  from 
[48]. 
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MDM2 has been found frequently overexpressed in AML, and may result in decrease or 
deletion of p53 activity [41-44]. MDM2 overexpression is associated with short complete 
remission durations and short event free survival rate, however no significant difference in 
overall survival [41, 42]. Inhibition of oncogenic MDM2 depletion of p53 would therefore be 
a possible therapeutic target in cancer therapy, and has gained a lot of interest in cancer 
research [47].  
 
1.3.1 Therapeutic approaches to restore p53 function by MDM2 inhibition in cancer 
and AML 
A number of approaches have been made in order to inhibit MDM2 repression of p53. 
Blocking of MDM2 expression, inhibition of MDM2 ubiquitin ligase activity and inhibition 
of MDM2-p53 binding are among mechanisms tested. A promising finding for MDM2 
inhibition is the diverging response induced in tumour cells versus normal cells. Tumour cells 
have been shown to response by undergoing apoptosis, whereas normal cells undergo cell 
cycle arrest [49]. In search for MDM2 inhibitors, several classes of compounds have been 
identified [39, 47, 50, 51]. Short, synthetic peptides mimicking the p53 fragments necessary 
for MDM2 binding have shown to be potent and non-toxic in stabilizing p53 [39]. A group of 
MDM2 inhibitors with a benzodiazepine core (Fig. 1.4A) have shown suppression of cells 
with wild type p53, however low cellular potency and selectivity [47]. Another compound, 
termed RITA (reactivation of p53 and induction of tumour cell apoptosis) (Fig. 1.4B), inhibits 
MDM2-p53 interaction by binding to p53 [47]. Quinolol (Fig. 1.4C), a compound identified 
using structure-based design, has shown potent antiproliferative activity and selectivity for 
wild-type p53 [47]. Common for many of these compounds is that their effect needs further 
confirmation and optimization. Inhibiting MDM2 may lead to disturbance of any other 
protein-protein interactions in which it is involved. Therefore a ligand specific for the 
MDM2-p53 binding site would be important to avoid unnecessary side effects.   
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Figure 1.4 Inhibitors of the p53-MDM2 interaction. Several classes of MDM2 inhibitors have been identified, 
here exemplified by the benzodiazepine core (A), RITA (reactivation of p53 and induction of tumour cell 
apoptosis) (B) and Quinolol (C).  
 
1.3.2 The MDM2 antagonists nutlin restore p53 function in AML 
A class of potent and selective small-molecule non-peptide cis-imidazoline analogues named 
nutlins were recently identified (Fig 1.5A.) [52]. One of the analogues, nutlin-3, prove to be 
an effective non-genotoxic anti-cancer agent in experimental models. Conformation and 
hydrophobicity are two critical requirements for interaction with MDM2 [33]. The 
imidazoline backbone in the nutlins functions as a scaffold both providing a rigid structure 
and enabling direction of the three crucial functional groups into their respective pockets, 
shown in Fig. 1.5 B with interaction of nutlin-2 and MDM2 [52]. The phenyl groups provide 
hydrophobicity. 
 
 
 
Figure 1.5 The nutlins. The cis-imidazoline analogues nutlin-1, -2 and -3 with their respective functional 
groups (A). The analogue used in this project was nutlin-3 (racemic). Nutlin-2 occupying the hydrophobic p53 
binding site on MDM2 (B). Nitrogen atoms shown in light grey, oxygen in darker grey, carbon in white and 
bromine in black. One bromophenyl group is occupying the Trp23 pocket of MDM2, the other occupying the 
Leu26 pocket and the ethyl ether side chain occupying the Phe19 pocket. Similarly will the chlorophenyl groups 
and the isopropyl group on nutlin-3 occupy the respective pockets [52]. 
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Nutlin-3 provides functional groups mimicking the residues necessary for binding of p53 in 
the hydrophobic groove of MDM2 and thereby specifically antagonizes the p53 binding site 
[52]. Cancer cell lines with wild type p53 showed accumulation of wild type p53 and 
subsequent activation of the p53 pathway upon exposure to nutlin-3 with a 50% inhibitory 
concentration (IC50) in the 100-300 nanomolar (nM) range. In vivo results showed 90% 
inhibition of tumour growth in xenografted tumours of an osteosarcoma cell line in Nude 
mice upon nutlin-3 treatment at oral doses of 200 mg/kg twice daily (b.i.d) for three weeks 
[52]. No significant weight loss or abnormalities upon necropsy were found, nor after three 
weeks of similar therapy regimen with the active enantiomer nutlin-3a alone [52, 53]. Primary 
AML cells have shown promising apoptotic response when exposed to nutlin-3 at non-toxic 
doses [43, 45]. AML cells show higher sensitivity to nutlin-3 than normal haematopoietic 
cells [43] and surviving cells show promotion of maturation [45]. Nutlin-3 induced 
differentiation has been proven for both p53 depleted and p53 wt cell lines, implicating an 
anti-leukemic effect additional to p53 activation [45]. 
 
In addition to overexpression of MDM2, aberrant recruitment of HDACs is a frequent 
occurrence HDACs in AML [54, 55]. As acetylation of p53 is a requirement for activity, this 
increased deacetylating activity may provide an additional strategy for p53 activation 
silencing in AML. Therefore, inhibition of HDACs may provide another potential target for 
AML therapy.    
 
1.4 Biology of histone deacetylases (HDACs) and function in AML 
Histone deacetylases (HDACs) are enzymes involved in epigenetic modulation and 
transcriptional repression, traditionally thought to be due to deacetylation of histones. 
Recently, however, they have been found to additionally deacetylate other cellular proteins 
such as transcription factors [54, 56]. HDACs are divided into four classes; Class I; HDAC 1, 
2, 3 and 8, class II; further subdivided into IIa; HDAC 4, 5, 7 and 9 and IIb; HDAC 6 and 10, 
class III, the sirtuin family (Sirh 1-7) and class IV consisting of HDAC 11. Deacetylation of 
the histones leave positive charged lysine regions on histone tails open, leading to compaction 
of chromatin due to negatively charged DNA back-bone. Acetylation neutralizes the positive 
charge, rendering the chromatin in a more open structure and more available for the 
transcriptional machinery. Aberrant recruitment of HDACs may therefore lead to silencing of 
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genes through chromatin compaction, as well as through inactivation of transcription factors. 
A number of hematopoietic transcription factors necessary for proliferation and maturation of 
hematopoietic cells have been found to be regulated by this mechanism, leading to 
hematopoietic malignancies [54]. AML-associated fusion proteins involving the transcription 
factors retinoic acid receptor (RAR) and eight twenty one (ETO), such as PML-RARα, 
AML1-ETO caused by chromosomal rearrangements, have been found to aberrantly recruit 
HDACs, leading to repression of target genes and differentiation block [55]. Additionally to 
recruit HDACs, the fusion protein PML-RARα physically associates with p53, thereby 
mediating deacetylation of p53 by HDACs [57]. Specifically, it has been demonstrated that 
p53 is directly deacetylated by class I HDACs, HDAC 1, 2, and 3, thereby directly silencing 
p53 activity [58], moreover that HDAC 1 is recruited by MDM2 and deacetylates p53 in a 
MDM2 dependent manner in vivo [59].  
 
1.4.1 HDAC inhibitors 
Six classes of HDAC inhibitors targeting class I/II HDACs have been identified classified on 
basis of structure (Fig. 1.6A); hydroxamic acid-type chelators, epoxyketones, carboxylates or 
short chain fatty acids, cyclic peptides, benzamides and hybrid molecules [60].  
 
 
Figure 1.6 The classes of HDAC inhibitors and the catalytic site on HDAC. One structure example from each 
of the six classes of HDAC inhibitors is shown, structural classes presented as 1-6 (A). The crystal structure of 
histone-deacetylase-like protein (HDLP) revealed a homologue of the mammalian HDAC class I/II (B). The 
catalytic site shown in colour; purple representing zinc ion, red active site, yellow representing channel and 
green representing the rim [61]. 
 
Great interest has emerged for the use of HDAC inhibitors in therapy of both cancer generally 
and AML specifically. The mechanism of action is by binding to distinct sites in the catalytic 
domain of class I and II HDACs [61]. This catalytic site has been found to contain a zinc ion 
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with channel leading therein and a rim surrounding the channel (Fig. 1.6B). A prerequisite for 
the inhibitory activity of HDAC inhibitors was revealed by structure activity relationship 
(SAR) as to be direct interaction between inhibitor and zinc ion [61]. Additionally, hydrogen 
bonding between the inhibitor and residues in the active site was detected. The 
pharmacophore of many HDAC inhibitors have been found to consist of domains interacting 
with residues in the rim and the channel; surface recognition domain and linker domain, 
respectively, and a metal binding domain which interacts with the active site and the zinc ion 
[61]. The efficacy of the different classes of HDAC inhibitors varies widely, from showing 
potency in the nanomolar range to the milimolar range [61]. Several HDAC inhibitors are 
currently undergoing clinical studies as anti-cancer agents. Suberoylanilide hydroxamic acid 
(SAHA) (Fig 1.6A), a hydroxamic acid targeting  class I and II HDACs, shows potency in the 
micromolar range in cells, and has been approved for treatment of cutaneous T-cell 
lymphoma [62]. The cyclic peptide FK228 (Fig. 1.6A) inhibits HDAC 1 and 2 in the 
nanomolar range, and has also reached phase II in clinical trials for treatment of refractory 
metastatic renal cell cancer [62]. MS-275 (Fig 1.6A) is a benzamide specifically inhibiting 
HDAC 1, 2 and 3 in the micro molar range [62]. MS-275 is in phase II clinical trials for 
treatment of metastatic melanoma [63] and phase I clinical trial for treatment of refractory 
solid tumours and lymphoid malignancies [64]. Depsipeptide is cyclic tertrapeptide which has 
shown anti-tumour effect against AML and is currently in a Phase II clinical trial for 
treatment of T-cell lymphoma [65]. 
 
In general, HDAC inhibitors induce histone acetylation, however the exact mechanism for the 
anti-tumour activity remains to be elucidated. Different models have nevertheless been 
suggested. One model suggests that increased acetylation of histones may lead to activation of 
tumour suppressor genes. This model is supported by findings of increased levels of the p21 
protein, a regulator of the cell cycle progression, and subsequent arrest in the G1 and G2 
phase in the cell cycle, leading to cellular differentiation [62, 65]. Additionally, death receptor 
mediated and intrinsic apoptotic pathways may be activated. A second suggestion is that 
hyperacetylation of histones may lead to genomic instability, and thereby trigger cell cycle 
arrest [65]. In addition to induce histone acetylation, HDAC inhibitors indirectly lead to 
acetylation of transcription factors, such as p53 [65]. It has been shown that apoptotic 
susceptibility of human cancer cells to the HDAC inhibitors trichostatin A (TSA) and SAHA 
was dependent on p53 [66]. TSA has additionally been found to increase p21 levels in a p53 
dependent manner [67]. Moreover, blasts remaining in the G0/1 phase of the cell cycle do not 
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show resistance to HDAC inhibitors, in contrast to chemotherapy [68]. As elderly patients 
tend to have increased amounts of blasts in the G0/1 phase, this observation implies a 
beneficial use of HDACs in elderly. Interestingly, normal cells are relatively resistant to 
HDAC inhibitors [62]. 
 
1.4.2 The traditional anticonvulsant valproic acid (VPA) as anti-cancer agent 
VPA (Fig. 1.7) is a short chain, branched fatty acid HDAC inhibitor, used for decades as an 
anticonvulsant. Because of its long time use VPA has a well-known pharmacologic profile.  
 
 
Figure 1.7 Structure of valproic acid. Interestingly, VPA was firstly used as a 
vehicle for other anticonvulsants, before its innate anticonvulsant effect was 
accidentally discovered in 1963 when used as a control [69]. 
 
 
VPA is highly ionized at physiologic pH and subsequently has a small volume of distribution 
of 0.13-0.19 L/kg. The plasma half life is approximately 15 hours. Plasma protein binding of 
VPA is about 90% and the majority of absorbed VPA undergoes  hepatic metabolism [68, 69] 
These pharmacokinetic properties provides VPA with an interaction potential with other drugs 
highly bound to plasma protein, or more importantly with other drugs either inhibiting or 
inducing hepatic metabolism enzymes, thereby increasing or decreasing VPA concentration. 
Alternatively, VPA may have similar effect on other drugs. VPA is metabolised by multiple 
pathways, resulting in more than 50 known more or less active metabolites [69], however is 
generally well-tolerated, side effects shown are sedation, dizziness, GI-toxicities and weight 
gain [12, 68, 69]. VPA was initially only used as anticonvulsant, but later it has also been 
used in treatment of migraine and neuropathic pain, and has in addition shown mood 
stabilizing effects [68]. The mechanism of action for these effects is not fully elucidated, but 
possibly involves increase in the inhibitory neurotransmitter γ-aminobutric acid (GABA) 
levels [68]. More recently, VPA has additionally been found to show HDAC inhibitory effect 
and has been used in several small clinical trials, both alone and in combination, towards 
treatment of  cancers, such as myeloid malignancies as AML [68]. As anti-leukemic agent, 
VPA has been found to show promising properties by affecting tumour growth and 
differentiation in leukemic cell lines [68]  inhibiting cell motility and tumour metastasis and 
show an anti-angiogenic effect [68] and an apoptotic effect [68, 70].  
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The carboxylate resulting from ionization upon administration of VPA is thought to 
coordinate with the zinc ion in the active site of the HDAC [60]. However, VPA interacts 
with the HDAC catalytic site with less efficacy than the hydroxamic acids, with an in vitro 
potency in the milimolar compared to nanomolar range as regards hydroxamic acids [60, 62].   
 
The antineoplastic effect of VPA  has been shown to largely depend on its HDAC inhibitory 
effect [71, 72]. VPA inhibits class I and IIa HDACs in the millimolar range [62, 73] and 
specifically induces proteosomal degradation of HDAC2 [74]. Research has proven that VPA 
inhibits corepressor-assoiated HDACs at therapeutically concentrations, in addition to act as 
potent inducer of differentiation in several types of transformed cells [71]. The anti-
proliferating effect of VPA on leukemic cells has been found to be regardless of p-
glycoprotein or MDR1 expression status, suggesting an implication for beneficial use in 
therapy of elderly AML patients [68]. Additionally, VPA shows anti-tumour activity in 
preclinical models of acute lymphoblastic leukaemia (ALL) and additionally inhibit 
splenomegaly due to leukemic infiltration, at doses of 200-250 mg/kg administered i.p. twice 
daily [75]. VPA administered after radiation induced stabilization of p53  in both normal and 
APL mice after administration of 400 mg/kg VPA i.p. [76]. Moreover, VPA treatment 
increased survival in the Brown Norway Myelogenous Leukaemia (BNML) rat [Unpublished 
observation, Emmet Mc Cormack]. VPA has additionally been used in several clinical trials, 
both alone and in combinations [68]. In one such trial, VPA as monotherapy in AML showed 
an overall survival of 11.5 months in responders and 5.65 in non-responders [21]. In 50% of 
patients with elevated white blood counts, VPA treatment was found to be sufficient to 
achieve antiproliferative effect. Additionally, AML cell blast differentiation was induced, 
independent on underlying genetic alterations. Despite that the effects of VPA were 
insufficient for use as monotherapy, VPA is suggested used in combination with inhibitors of 
other pathways known to be altered in AML [21]. However, it should be noted that 
susceptibility to VPA treatment (and other HDAC inhibitors) in AML patients has been found 
to vary individually, even between patients showing similar genetic alterations [77]. 
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1.5 Combining non-genotoxic p53 activating agents as a potential novel 
strategy for AML treatment 
Combining anticancer agents may be appreciable for various reasons [78]. Two agents with 
different mechanism of action may show non-overlapping toxic effects, possibly allowing a 
higher anti-tumour effect without increasing overall toxicity to the patient. Additionally, such 
combination regimens may inhibit development of resistance to the single agents. 
Furthermore, there is a possibility that the agents act synergistically.  VPA as HDAC inhibitor 
inhibits chromatin compaction and thereby transcriptional repression caused by HDACs, in 
addition to inhibit deacetylation of the transcription factor and tumour suppressor gene p53. 
Nutlin-3 indirectly activates p53 by inhibiting the main negative regulator of p53, MDM2. 
These two agents both render p53 ready to be acetylated and activated. However, VPA is not 
an effective anti-cancer agent given alone, nevertheless its mechanism of action have shown 
that it increases response to other therapy, such as ATRA.  
 
We postulated that a combination of two agents indirectly activating p53 by two different 
mechanisms would provide a possible novel therapeutic strategy in the treatment of AML. 
 
1.6 Experimental models 
1.6.1 In vitro model 
The experimental in vitro model used in this thesis is an AML cell line, established from 
human tumour cells [79]. AML cell lines are characterized by monoclonal origin, 
differentiation arrest, sustained proliferation and specific genetic alterations. The unlimited 
supply and world wide availability enables comparable results worldwide. The specific AML 
cell line used in this project for in vitro evaluation of therapy was the human AML cell line 
MOLM-13 (FAB M5) expressing wild type p53 [43]. For evaluation of in vitro drug efficacy, 
three different assays were used; the apoptosis detecting Hoechst 33342, the cellular 
metabolic activity measuring Alamar blue assay, and the bioluminescent ATP assay using 
cellular ATP as endpoint.  
 
1.6.2 Preclinical models 
Cell lines are excellent models providing an indication of therapeutic effect. Unfortunately, 
cell lines do not provide a complex system addressing cellular or therapeutic interactions with 
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a biological environment, while in vivo studies in humans are constrained due to ethical 
reasons. Therefore, further evaluation of therapy requires other complex biological and 
physiological systems, providing also pharmacokinetic and pharmacodynamic properties 
closer to humans. Such a model should, however, also enable translation from in vitro results. 
 
A variety of inbred rat strains and genetically engineered mice strains have been developed in 
order to approach a beneficial preclinical biologic system of AML [80-82]. A valuable model 
of such is the Brown Norway Myelogenous Leukaemia (BNML) model. This leukemic rat 
model was developed in 1971, when injection of a carcinogen induced myeloid leukaemia 
[83]. The disease model shares many characteristics with human AML as responding to 
chemotherapeutic combinations effective in human AML and  suppression of normal 
haematopoiesis similar to human AML [83]. The BNML rat, however, is p53 null 
(unpublished observations E. McCormack), limiting its potential as model for evaluation of 
p53 activating therapy. Genetically engineered mice have been developed to provide specific 
genetic alterations found in AML enabling study of leukaemogenesis [80]. In a preclinical 
pilot study of a specific molecular targeted therapy, however, translation of therapy efficacy 
from a specific cell line to an in vivo model requires a similar karyotype of disease as 
provided by the cell line. For such a purpose, xenotransplantation models are excellent as 
their immunodeficiency allows engraftment of human cell lines, e.g. the MOLM-13 cell line.  
 
1.6.3 Xenograft models and imaging 
The non-obese diabetic/severe combined immunodeficiency interleukin-2 gamma null 
(NOD/SCID IL2 γnull) strain of mice is a preclinical xenograft model characterized by 
complementary 5 (C5) deficiencies and lack of functional T- and B-cells. Additional 
characterization is lack of a functional common IL-2 receptor γ-chain leading to block of 
natural killer (NK) cell development and other deficiencies in the innate immunity [80, 84]. 
The result is an immunodeficient model susceptible for engraftment of human cell lines, such 
as the AML cell line MOLM-13 [85], enabling translation of therapeutic evaluation from in 
vitro to in vivo [86]. The immunodeficiency may provide a drawback in therapy evaluation, as 
some therapies induce effect of the immune system. Such immune response will subsequently 
not be addressed in this model. Nevertheless, in a pilot study evaluating a potential therapy 
strategy, the property of providing a disease with known karyotype is essential.  
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Xenotransplantation of a human cell line should be in the tissue of origin, i.e. in the 
circulation for AML cells. Solid subcutaneous tumours allows monitoring of disease 
progression and therapeutic effect by manually measuring tumour size using a caliper [87]. 
Similar staging of disease is impossible in AML preclinical models, as development of 
disease includes infiltration of various organs, such as bone marrow, lymphoid organs, the 
central nervous system (CNS) and high blood throughput organs as liver and spleen. To 
reduce amount of animals needed for disease staging and longitudinally monitoring of 
therapeutic effect in AML models, alternative non-invasive methods are needed whereby 
therapeutic intervention time point additionally may be determined. Small animal imaging 
modalities providing whole-body, deep-tissue imaging are excellent alternatives providing the 
above mentioned properties [88]. Magnetic resonance imaging (MRI), positron emission 
tomography (PET) and optical imaging are examples of imaging modalities used in the above 
mentioned purpose. MRI and PET requires expensive equipment, PET additionally demands 
synthesis of positron labelled molecules, subsequently requiring specialized personnel and a 
cyclotron [89, 90]. Optical imaging requires less resources than MRI and PET, is relatively 
cheap and easy to use [87, 89]. Molecular imaging is a highly appreciated method in 
oncologic drug development [88], almost a pre-requisite for US Food and Drug 
Administration (FDA) drug approval, and optical imaging is widely used in the 
pharmaceutical industry. 
 
1.7 Optical imaging and reporter systems as tools for therapy evaluation 
Optical imaging presents a valuable preclinical tool allowing non-invasive detection of early 
disease and disease development pattern, quantitative localization of disease and therapy 
response monitoring [88]. Utilization of fluorescent or chemiluminescent properties of certain 
optical reporters allows in vivo detection of cells labelled with such reporters. Limiting 
aspects as regards optical imaging are the properties of light regarding depth of penetration 
and scattering. Nevertheless, as light attenuation is limited in small animal such as mice, 
optical imaging presents a good opportunity of tracking labelled AML cells, thereby allowing 
disease detection and therapy efficacy supervision.  
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1.7.1 Fluorescent and bioluminescent reporter genes  
For all reporter gene imaging studies, delivery of a reporter gene to the target tissue or the 
cells engrafted is a requirement. Additionally, a stable reporter system provides an 
opportunity for repetitive imaging. Fluorescent reporter genes require an excitation light 
source at a defined wavelength, as described in Fig. 1.8. 
 
Figure 1.8 Principles of fluorescence explained by    
Jablonski diagram [91]. An excitation light at a defined 
wavelength excites a particular fluorophore to reach a higher 
level of energy (S1 or higher). As the fluorophore at this state 
is very unstable, it drops to the lowest level of excitation, 
releasing some of its energy as heat. From this state, the 
fluorophore eventually adopts its original state (S0), a process 
releasing energy in form of light. This emitted light has lower 
energy than the absorbed light and therefore longer 
wavelength, subsequently represented in a different region of 
the light spectrum than the excitation                                light.  
 
 
The green fluorescent protein (GFP) is a fluorescent reporter originally isolated from the 
jellyfish Aequoria Victoria. New derivatives have been developed, such as cyan fluorescent 
proteins (CFP), yellow fluorescent proteins (YFP) and red fluorescent proteins (RFP). GFP is 
excited in the blue region of the light spectrum at ~470 nm, and emits light in the green region 
at ~510 nm [87]. An issue to consider when using GFP as reporter gene protein in optical 
imaging is the endogenous autofluorescence of tissues which both may limit sensitivity and 
specificity of the imaging. GFP, however, is very useful if samples are taken to be analyzed 
using flow cytometry [92]. 
 
Bioluminescent reporter gene protein products, termed luciferases [93], do not require 
excitation light as the light emission is a result of an enzyme-catalyzed chemical reaction. 
They, however, require the delivery of a substrate, luciferin, to the reporter gene expressing 
cells to initiate a light-producing reaction, exemplified in Fig. 1.9 by the firefly luciferase. 
The luciferin is a water-soluble substrate with high cell membrane permeability, which causes 
minimal toxicity [87]. 
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Figure 1.9 The firefly luciferase originates from the 
American firefly, Photinus pyralis. The chemical reaction 
responsible for bioluminescence depends on luciferin, 
oxygen (O2), magnesium (Mg2+) and adenosine 
triphosphate (ATP) [94]. The oxyluciferin first yields an 
electronically excited state, before returning to ground 
state and thereby emitting light with a wavelength of max 
intensity of 562-570 nm. AMP,adenosine monophosphate; 
PPi, pyrophosphate.                                                                                           
 
 
In vivo bioluminescent imaging has widely been used for whole body imaging of small 
animals [95]. Moreover, the technique has been successfully used in evaluation of anti-
leukemic therapy in vivo [96, 97], e.g.in the study of a molecular targeted combinational 
therapy of AML in vivo, specifically targeting the FLT3 protein and inhibitors of apoptosis 
(IAPs) [97]. The technique carries the advantage of being very sensitive due to low 
background noise and absence of autobioluminescence as mammalian tissue is not light 
emitting, and therefore even very small amounts of bioluminescent signals can be detected 
[87, 92]. 
 
Absorption and scattering of light penetrating biological tissue may attenuate the optical 
signal obtained from fluorescent and bioluminescent reporters emitting light in the 
wavelength spectrum of the blue-green region (400-600 nm). Haemoglobin and 
oxyheamoglobin strongly absorbs light at wavelengths shorter than 600 nm [98]. This 
property especially influences AML imaging as AML cells are mainly present in blood and 
blood-filled organs. The deeper the signal, the greater influence will absorption and scattering 
have on the optical signal. However, such absorption of light is strongly reduced in the near 
infrared (NIR) window (700-900 nm).  
 
The use of fluorescent dyes with wavelengths in the NIR range, e.g. cyanines, suggests a 
better visualization of AML disease according to the above mentioned properties of light in 
this region. Additionally, autofluorescence is lower in the NIR compared to shorter 
wavelengths [98]. However, specific targeting of fluorescent probes to tumour cells may give 
rise to problems with unspecific binding. Thus, generation of AML cells expressing an 
enzyme capable of unquenching a pro-fluorescent dye introduces a solution to overcome such 
issue. The nitroreductase (NTR) enzyme from the bacteria Escherichia coli B provides the 
property to reduce nitro groups on its substrates, and has subsequently been used as an 
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activator of nitro-containing pro-drugs [99]. By a similar mechanism, NTR can unquench the 
pro-fluorescent cyanine dye CytoCy5S to yield a fluorescent dye with emission wavelength in 
the NIR. CytoCy5S is a lipophilic substrate which easily and non-destructively permeates the 
cell [100]. As eukaryotic cells do not express NTR naturally, unquenching of the dye will be 
restricted to NTR expressing AML cells, thereby providing an appropriate system for 
detection of disease and therapy efficacy in preclinical AML models. 
 
1.8 Aim of study 
AML is an aggressive disease which mainly strikes the elderly proportion of the population. 
In the western part of the world, the average life expectancy is increasing and accordingly the 
number of patients diagnosed with AML is predicted to increase. Given that there are very 
limited therapeutic alternatives, and that the standard therapy at present is non-tolerated for a 
large proportion of the patients, there clearly is a need for novel, more specific targeted 
therapy showing less toxicity. The low frequency of mutated p53 in AML additionally to 
frequent MDM2 overexpression and aberrant recruitment of HDACs suggests a non-
genotoxic p53 activating strategy as a therapy strategy of such. Thus, the aim of this study 
was to evaluate a novel therapy strategy using a combination of the well-known HDAC 
inhibitor valproic acid (VPA) and the novel, more specific targeting MDM2 inhibitor nutlin-3, 
both agents inducing p53 activity. The therapy would be evaluated both in vitro and 
subsequently in vivo, using optical imaging. 
 
In order to achieve this, the more specific aims were to: 
• Evaluate the efficacy of the combinational therapy of nutlin-3 and VPA in a relevant 
cell line, i.e. the MOLM-13 AML cell line expressing wt p53 using relevant cell 
viability assays 
• Establish an imageable in vivo xenograft model of MOLM-13 to evaluate and translate 
in vitro result in vivo 
• Evaluate preliminary toxicity of nutlin-3 and VPA 
• Perform a pilot therapy study to evaluate the efficacy of the combinational therapy of 
nutlin-3 and VPA in vivo in a xenograft model of MOLM-13 AML by using optical 
imaging 
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1.9 Methodological strategy 
• DNA-specific staining with the fluorescent dye Hoechst 33342 allows detection of 
apoptosis by morphological examination of the nucleus, whereas Alamar blue and 
ATP assays provide information of cell viability by evaluation of cellular redox and 
energy state, respectively, thereby providing the opportunity to evaluate efficacy of 
treatment of cells with therapeutic compounds. 
• Using retroviral transfection, MOLM-13 cells may be stably labelled with the reporter 
genes GFP and NTR. Optimisation of fluorescent expression and selection of highly 
fluorescent clones may be performed by Fluorescence Activated Cell Sorter (FACS) 
• Similarly, MOLM-13 cells can be made to stably express Luciferase. Optimisation of 
bioluminescent expression will be performed by sorting the live population using 
FACS, and selection of highly bioluminescent clones may be performed by using 
time-domain small animal optical imager (TD-SAMI) 
• Finally, using TD-SAMI, disease development and treatment efficacy may be studied 
and evaluated for in vivo AML models xenografted with MOLM-13 reporter gene 
cells. 
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2 Materials 
 
Table 2.1: Cell lines 
Cell line Supplier or construct details 
MOLM-13 (wt); human acute myeloid 
leukaemia (AML) cell line with wild type 
p53 
The German resource centre for biological 
material (DSMZ) 
MOLM-13 L149 cells Transfected with GFP, Luciferase and NTR 
MOLM-13 L192 cells Transfected with Luciferase 
Phoenix cells; Amphotropic packaging 
cell line 
Prof. James B. Lorens, Institute of biomedicine, 
University of Bergen 
Table 2.2: Materials used in cell culture 
Material Supplier 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
DMEM Sigma-Aldrich 
Fetal Bovine Serum (FBS) Standard Quality PAA Laboratories GmbH 
L-glutamine (2 mM) Sigma-Aldrich 
Penicillin (5000 units/ml)-Streptomycin (5 
mg/ml) 
Sigma-Aldrich 
RPMI-1640 Medium Sigma-Aldrich 
Saline (Nacl 0.9 %) B.Braun 
Vircon Antec International A DuPont Company 
Table 2.3: Drugs and materials used for evaluation of combinational therapy 
Material Supplier 
Alamar blue Sigma-Aldrich 
CellTiter Glo® buffer   Promega 
CellTiter Glo® substrate Promega 
Formaldehyde solution, min 37 % Merck 
Hoechst 33342 Invitrogen 
Hydroxypropyl cellulose Sigma-Aldrich 
Nutlin-3 Cayman Chemical Company, Michigan, USA
Tween-80 Sigma-Aldrich 
Valproic acid (Orfiril) Desitin Arzneimittel GmbH, Hamburg, 
Germany                      
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Table 2.9 Materials used in transfection of MOLM-13 cells 
Material Supplier 
2X HeBS (1L): 
- 20 ml 75 mM Na2HPO4 
- 16 g NaCl 
- 13 g HEPES sodium salt 
- ddH2O to 1000 ml 
 
Merck 
Fisher 
Sigma Aldrich 
Chloroquine Sigma Aldrich 
2 M CaCl2 Baker 
Plasmid DNA (L149, L192 and tTA 
construct, see Fig. 2.1) 
Prof. James B. Lorens 
VSV G pseudotyped virus Prof. James B. Lorens 
Protamine sulphate (1:1000 of 25 mg/ml 
stock) 
Sigma Aldrich 
Puromycin dihydrochloride (selection agent) Sigma Aldrich 
 
 
 
 
Figure 2.1 Maps of vectors used in retroviral transfection of MOLM-13 cells. (A) The L149 vector with a 
puromycin resistant gene, followed by GFP, Luciferase and NTR. The 2A segment is the site of cleavage during 
translation, giving single proteins. (B) The L192 vector with puromycin resistant gene followed by Luciferase. 
(C) The TetActivator vector with TetActivator followed by a hygromycine resistant gene. (All maps modified 
from maps provided by David Micklem, Insitute for Biomedicine, University of Bergen.) 
 
Table 2.10 Substrates used in NTR and Luciferase studies 
Dye Supplier 
CytoCy5S Amersham Biosciences 
D-Luciferin Firefly, potassium salt (synthetic) Biosynth® 
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Table 2.11 Technical equipment 
Equipment Supplier 
Aluminium foil CaterwrapTM 
Burker chamber; 0.100 mm depth, 0.0025 
mm2 
Marienfeld 
Beckman polyallomer tubes Beckman Coulter 
SW41Ti rotor Beckman Coulter 
Cell strainer 40 µm BD Biosciences 
Centrifuge 5810 R Eppendorff 
CryoTubeTM Vials Sarstedt 
Examination gloves Clinic®
eXplore Optix TM TD-SAMI ART Inc./GE Healthcare 
FACSAria SORP BD Biosciences 
FACS Calibur flow cytometer Becton Dickinson 
Forma Bio-Freezer Forma Scientific 
Insulin syringe Tyco healthcare, kendall monoject 
Laminar flow bench  Holten LaminAir 
Leica DM IRB fluorescence microscope Leica 
Micro 22R centrifuge Hettich Centrifuges 
Micro tubes 1.5 ml Sarstedt 
Micropipettes  Eppendorff 
MilliQ Water Purification Systems Millipore 
Nikon eclipse TS100 microscope Nikon 
Nitrogen tank Taylor-Wharton 
Omnifix®, dosage syringes B.Braun 
Parafilm Pechiney Plastic Packaging Company 
Pipet tips Molecular Bioproducts 
Pipet-aid Integra Biosciences 
Seri-Cycle CO2 Incubator with HEPA filter ThermoForma 
Serological pipettes  VWR 
Spectrafuge mini Labnet International Inc. 
Spectramax Gemini Fluorometer Molecular Devices 
Sterifix® filter 0.2, 0.45 µm B.Braun 
Stainless steel disposable oral dosing needles 
with silicone tip for mice 
Scanbur 
Tissue culture flasks Techno Plastic Products AG  
Tissue culture test plates 6-, 24- and 96 well 
plate 
Techno Plastic Products AG  
Universal 32 R sentrifuge Hettich Centrifuges 
Vortexer IKA® Laboratory equipment 
Water-Bath, Heto HWT 100 Heto-Holten A/S 
15 ml and 50 ml PP-Falcon tubes Greiner Bio-One 
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Table 2.12 Analytical software 
Software Analysis Supplier 
Adobe Image Ready 7.0 Fluorescence microscopy Adobe 
Adobe Illustrator CS Edition of TD-SAMI images Adobe 
Adobe Photoshop CS Edition of TD-SAMI images Adobe 
eXplore Optix Optiview Analysis of TD-SAMI images ART Inc. 
eXplore OptiViewer 1.02.01 Analysis of TD-SAMI images ART Inc. 
FlowJo Version 8.3.3 Analysis of FACS Tree Star Inc. 
GraphPad Prism 3.0 Statistical analysis GraphPad Software, Inc. 
SoftMax Pro Analysis of absorption/ 
emission in Spectramax 
Gemini Fluorometer 
Molecular Devices 
Table 2.13 Filter sets 
Apparatus Exitation wavelength (nm) Emission wavelength (nm) 
FACS Calibur + 
FACSAria SORP 
FL1-H 488 530/30 band-pass (BP) 
FL4-H 635 661/16 BP 
Fluorescence  
Microscope 
470/40 BP 525/50 BP 
515-560 BP 590 long-pass (LP) 
Spectramax  
Gemini  
Fluorometer 
Alamar 
Blue 
530 590 
 
ATP 
assay 
 562  
Table 2.14 Animals 
Mouse strain Supplier 
NOD/SCID Gades Institute, University of Bergen, 
originally Jackson Laboratories, Bar Harbour, 
Maine, USA 
NOD/SCID IL2γnull Gades Institute, University of Bergen, 
originally Jackson Laboratories, Bar Harbour, 
Maine, USA 
Table 2.15 Animal equipment 
Equipment Supplier
BCC Dynarray 4 mV photon irradiation 
source 
BCC Dynarray 
Cordless trimmer (ChroMini) MOSER 
Disposable oral dosing needles, stainless steel 
with silicone tip 
Scanbur 
Isoba vet Isofluorane Schering-Plough Ltd 
IVC cage (Green-line) TECNIPLAST Sealsafe® 
Low Fluorescence Food KLIBA NAFAG 
Scanbur bedding Abedd 
Simplex (eye ointment) Hydro Pharma 
Surgical blades Swann-Morton® 
Veet® (depilatory cream) Recitt Benckiser 
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3 Methods 
 
3.1 Cell experiments 
3.1.1 Cell culture 
All cell work was carried out under a sterile environment using a laminar flow bench with 
HEPA filter. Cells were kept in a CO2-incubator at 37°C with CO2 levels at 5%, and observed 
under microscope on a daily basis to ensure optimal proliferative and bacterial free 
conditions. 
 
MOLM-13 cell lines were cultured in a complete medium consisting of Roswell Park 
Memorial Institute (RPMI)-1640 medium, 10% Fetal Bovine Serum (FBS), 1% 
Penicillin/Streptomycin (PS) and 1% L-Glutamine (L-G). FBS was incubated in a water bath 
at 56°C for 40 minutes in order to inactivate heat-labile complement components. 
 
Cells were thawed by transferring cryotubes containing 5-10 x 106 cells from a liquid nitrogen 
tank to a laminar flow bench, where thawed rapidly at 37°C until almost completely 
defrosted. To the cells was added 1 ml complete medium and were left to recover for 5 
minutes at room temperature (RT), thereafter transferred to a 15 ml tube containing 10 ml 
complete medium. The cells where then pelleted at 1600 rpm at RT for 8 minutes, washed x2 
with complete medium to remove the cryoprotectant dimethyl sulfoxide (DMSO), and 
cultured with 10 ml complete medium in a 75 cm2 culture flask. 
 
MOLM-13 cells were split in a ratio of 1:3 with new complete medium when at a 
concentration of 1.5 x 106 cells/ml. Medium was changed or replenished twice a week until 
the cells needed to be split again. 
 
3.1.2 Freezing of cells 
The cells were frozen in freezing-medium consisting of 20 % FBS, 10 % DMSO and 70 % 
RPMI. Cells were counted, pelleted at 1500 rpm for 10 minutes at 4°C and washed x2 in 1X 
PBS, before being resuspended in freezing medium and transferred to 1.5 ml cryogenic vials 
(5-10 x 106 cells per vial). Vials were stored at -80°C overnight, and thereafter transferred to a 
liquid nitrogen tank for long term storage at -196°C.  
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3.2 Evaluation of viability/apoptosis after drug treatment  
Different concentrations of nutlin-3 and valproic acid (VPA) were applied to the MOLM-13 
cell line (250 000 cells/ml) in 96-well plates. Evaluation of treatment efficacy was performed 
either by Alamar blue assay, Hoechst staining or ATP assay.  
 
3.2.1 Alamar blue assay 
The Alamar blue (resazurin) assay is a fluorogenic reduction-oxidation indicator of viability 
of cells in culture. Resazurin is a non-fluorescent, dark blue dye, which is reduced by 
mitochondrial and cytosolic enzymes in living cells to yield resorufin, a pink and highly 
fluorescent dye [101]. The degree of fluorescence thereby directly presents the viability of the 
cells, where decrease in fluorescence presents reduction in viability.  
 
10% Alamar blue was applied to the cells after 24, 48 and 72 hours incubation with drugs. Per 
cent viability of control was calculated after 4-6 hours incubation with Alamar blue by 
detection of fluorescence in a Spectramax Gemini Fluorometer. 
 
3.2.2 Hoechst staining 
Bisbenzimide binding Hoechst 33342 is a cell-permeable, fluorescent dye which specifically 
binds and stains DNA at adenine-thymidine residues. Using fluorescence microscopy, this 
allows studying of cell nuclei morphology and thereby manually counting of apoptotic and 
normal cell nuclei in a sample. 
 
In order to fix and stain the treated cells, 40 µg of Hoechst 33342 was added to 1 ml solution 
of 8 % formaldehyde in PBS. After the same periods of incubation with the various drug 
concentrations as described in section 3.2.1, 100 µl of this solution was added in each well to 
yield a concentration of 20 µg/ml. % apoptosis was calculated after apoptotic and normal cell 
nuclei were counted. 
 
3.2.3 Adenosine triphosphate (ATP) assay 
The rapid adenosine triphosphate (ATP) assay utilizes the bioluminescent measurement of 
ATP in order to detect viable, metabolically active cells e.g. after exposure to a cytotoxic 
compound.  The number of viable cells can directly be related to quantity of ATP present, as a 
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reasonably uniform amount of ATP is present in each metabolically active cell [102]. The 
reagent used lyses the cell membrane to mediate release of ATP and additionally inhibits 
ATPases. By finally providing luciferase and luciferin, the reagent allows a bioluminescent 
reaction to occur and bioluminescence intensity may be measured.  
 
100 ml of the ATP assay buffer was added to the proper vial of the ATP assay substrate as 
described in protocol from supplier in order to make the reagent. After the same time points as 
described in section 3.2.1, plates with treated cells were left in RT for 30 minutes along with 
reagent, before 100 µl of reagent was added to each well. One well containing only medium 
and reagent was used as background. The plate was carefully shaken for two minutes. After 
10 minutes, bioluminescence was measured by using a Spectramax Gemini Fluorometer.  
 
3.2.4 Calculation of synergism 
To investigate if some of the effect of a combinational therapy in vitro was due to synergism, 
Bliss Independence model was used [103]. Conditions for using the model is that the two 
therapeutic agents do not directly interfere with each other and that they have different targets, 
i.e. they are independent. However, they may have a common outcome.  
 
To look for synergy, response to each of the drug alone at specific concentrations must be 
obtained. The expected response to the combination of the specific concentrations may then 
be calculated using equation 3.1: 
Ix,y = Ix + Iy - IxIy         (3.1) 
where Ix.y is the expected response to the combination of drug X and Y, Ix and Iy are the 
fractional responses to each of the single agents X and Y at concentrations Cx and Cy. Positive 
difference between real response and expected response is ascribed to synergism, exemplified 
in Fig 3.1. 
 
Figure 3.1  Bliss Independence. Example of antagonistic and synergistic 
effects. Expected effect of an imaginary combination is set to 0. Bars 
represent real response. If the real response is as exemplified with A, 
difference between real response and expected response is negative, 
implying antagonism. A real response yielding a positive difference 
between real response and expected response, such as exemplified with B, 
implies synergism. 
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3.3 Transfection of MOLM-13 cells 
Several attempts were made to transfect MOLM-13 cells with L149 and tTA, and L192 and 
tTA constructs (see table 2.2 for details) and different protocols [104] were used. 
 
3.3.1 Virus production 
1.0 x 106 Phoenix cells (retrovirus producer) in 1.5 ml Dulbecco’s Modified Eagle’s Medium 
(DMEM) completed with 10 % FBS, P/S and L-G were seeded out in 6-well plates 24 hours 
prior to transfection. Immediately before the transfection procedure, 2 µl of 50 mM 
chloroquine was added to the cells to inhibit lysosomal DNA degradation [105]. 32 µl of 2.5 
M calciumchloride (CaCl2) was added into two separate 15 ml tubes. In one tube, 1.5 µl 
plasmid DNA (L149 and tTA) and 216,5 µl sterilized H2O was added. In the second tube, 3 µl 
plasmid DNA (L192 and tTA) and 215 µl sterilized H2O was added. To both tubes was added 
250 µl 2x HEPES-buffered saline (HeBS), immediately followed by air-bubbling for 10 
seconds using an autopipette, in order to form fine precipitates. These solutions were then 
drop wise added to separate 6-wells containing the Phoenix cells. The plate was incubated for 
8-16 hours, before cells were washed x1 with 1X PBS and new medium added. After further 
incubation of approximately 60 hours, the virus supernatant was collected and filtered through 
a 0.45 µm filter.  
 
3.3.2 Virus production with concentration of virus 
The procedure was scaled up from the protocol described above to enable to virus 
concentration of virus supernatant. 5 x 106 Phoenix cells in complete DMEM media as 
described above, were seeded out on 10 cm plates. 24 hours later 10 µl 50 mM chloroquine 
was added to each plate. 50 µl of 2.5 M calciumchloride (CaCl2) was added into two separate 
15 ml tubes. 5 µl plasmid DNA (L149, tTA, VSV G) and 445 µl sterilized H2O was added to 
one tube, 10 µl plasmid DNA (L192, tTA) and 440 µl sterilized H2O was added to the other. 
To both tubes was then added 500 µl 2x HEPES-buffered saline (HeBS), immediately 
followed by air-bubbling as described previously (section 3.2.1). The protocol from section 
3.2.1 was followed until subtraction of the virus supernatant. After filtering, the supernatants 
from plates containing the same retroviral construct were pooled and centrifugated at 28 000 
rpm at 4°C for 3 hours. The supernatant was carefully decanted away and pellets resuspended 
in 500 µl PBS, and kept overnight at 4°C.  
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3.3.3 Infection of MOLM-13 cells  
To the virus supernatant, protamine sulphate, an agent used to enhance gene transfer [106], 
was added to a final concentration of 5 µg/ml. 1 ml of the solution of was added to 6-well 
plates containing 0.1 x 106 MOLM-13 cells in each well. The plate was incubated for 24 
hours, before infected a second time, using the same procedure. After further 24 hours 
incubation, the virus supernatant was displaced with normal virus-free media. All virus-
containing waste was inactivated with Vircon. 
 
3.3.4 Spin infection of MOLM-13 cells 
Protamine sulphate was added to the virus supernatant to a concentration of 5 µg/ml, 
thereafter 1 ml of the solution was added to a 6-well plate containing 0.1 x 106 MOLM-13 
cells in each well. The plate was sealed with parafilm and centrifuged at 1200 g for 90 
minutes at room temperature (RT), followed by incubation until the cells looked healthy (2-3 
days), assessed by light microscopy. A second infection was performed following the same 
procedure, followed by further incubation. After 24 hours the media was replaced with normal 
virus-free media. All cell culture waste containing virus was inactivated with Vircon.  
 
3.3.5 Puromycin selection of MOLM-13 L149 tTA and L192 tTA cells   
Both the L149 and the L192 vector contain a puromycin resistant gene (Fig. 2.1), allowing 
antibiotic aided selection of successfully transfected cells from wild type cells. Thus, the cells 
were pelleted at 1600 rpm for 8 min at RT, washed x1 with 1X PBS, added new medium 
containing puromycin (1 mg/ml). The same amount of puromycin was added a well 
containing non-resistant wt MOLM-13 cells. When all wt cells were dead, selection was 
stopped and remaining transfected cells were washed, pelleted and transferred to a small cell 
culture flask and grown. 
 
To obtain stably transfected clones expressing high level of proteins of interest, both MOLM-
13 L149 cells and MOLM-13 L192 cells were thoroughly sorted by fluorescence-activated 
cell sorting (FACS).  
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3.4 Flow cytometry 
The use of flow cytometry, or fluorescence-activated cell sorting (FACS), allows examination 
of both morphologic and fluorescent properties of single cells in a suspension [107], principle 
described in Fig. 3.2. This multi parametric analysis can be used either to select the most 
viable or the most fluorescent clone amongst many, or cells in a suspension can be sorted out 
one by one on basis of the properties described, to give rise to new clones. For clone 
selection, 10 000 cells were acquired from a cell suspension, followed by quantification of 
fluorescence by the selected channel. The cells were gated for the viable population (as shown 
in Fig. 3.3) and analyzed by the FlowJo software. 
 
 
 
Figure 3.2 Flow cytometry. The single cell suspension flows through a detection point of the apparatus, where 
hit by a laser beam (A). Information about size and granularity is obtained, respectively, through detection of a 
forward scatter (FSC) resulting from refraction and a side scatter (SSC) resulting from reflection of this light. 
Additional detectors of fluorescence (photo multiplier tubes; PMT) gives the possibility to quantify light emitted 
from a cell as it is excited by a laser beam; in this thesis the FL1-H channel was used for measuring green 
fluorescent protein (GFP) and the FL4-H channel for measuring NTR-dye fluorescence (see Table 2.10).  Based 
on information from the flow cytometry analysis, sorting of target cells may be performed (B). Creation of 
charged liquid droplets containing target cells is performed by charging the liquid just before a drop containing 
target cells is made, droplets made by oscillation. As droplets fall from the nozzle, deflection of only the charged 
droplets is performed by a deflection plate, subsequently allowing isolation and collection of target cells. Figures 
from [108]. 
 
3.4.1 Incubation of NTR+ cells with CytoCy5S 
0.4x 106 MOLM-13 L149 cells were pelleted at 1600 rpm for 8 minutes at room temperature 
and washed x1 with 5 ml 1X PBS. The pellet was resuspended in 1.8 ml complete medium 
and placed out in a 24-well plate. 200 µl of 10 µM CytoCy5S (dissolved in DMSO, diluted 
with complete medium) was added to the well to give a total concentration of 1 µM. After 1 
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hour incubation, the cell-solution was transferred to 15 ml tubes, pelleted and washed x2 with 
1X PBS.  
 
3.4.2 Preparation of cells for flow cytometry 
1.0 x 106 cells pr sample were pelleted at 1600 rpm for 8 minutes in RT and washed x1 with 
1X PBS. The pellet was resuspended in 300 µl 2% paraformaldehyde (PFA) fixative and run 
on FACS within 0-5 days. Exclusion of non-viable cells and debris was done by gating in the 
FACS Calibur acquisition software (as shown in Fig 3.3). 
 
3.4.3 Preparation of cells for sorting by FACS 
To make cell-clones with a stable, high expression of GFP and NTR, cell-sorting by FACS 
was performed. MOLM-13 L192 expressing luciferase was sorted by FACS, however solely 
on basis of viability. 
 
10 x 106 cells were counted, pelleted and washed x2 in 1X PBS. MOLM-13 L149 cells were 
incubated with 1 µM CytoCy5S, as previously described (Section 3.4.1). After washing with 
1X PBS, pellets were resuspended in 1X PBS to a concentration of 0.5 x 106 cells per ml. A 
control sample with 0.5 x 106 MOLM-13 wild type cells was prepared under identical 
conditions.  MOLM-13 L192 cells were resuspended in 1X PBS to the same concentration. 
All cell solutions were then filtered using a 0.45 µm filter. MOLM-13 L149 cells were sorted 
on basis of high expression of GFP and NTR-dye fluorescence intensities (illustrated in Fig. 
3.3), whereas MOLM-13 L192 cells were gated on basis of viability (i.e. FSC and SSC). Both 
cell lines were sorted one by one into the wells on 96-well plates prefilled with complete 
medium. The cells were incubated until colonies could be observed, and transferred to 24-well 
plates and added new medium.  
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Figure 3.3 Sorting of MOLM-13 L149 tTA and MOLM-13 L192 tTA cells by FACS.  
The acquired cells were first gated for the live population on basis of FSC and SSC (encircled) (A). MOLM-13 
L192 tTA cells were sorted one by one into wells on a 96-well plate after this gating. MOLM-13 L149 tTA cells 
were further gated for high GFP and NTR expression (encircled) (B) before sorted one by one into wells of 96-
well plates. (All cell sorting was performed by Marianne Enger.) 
 
3.4.3.1 Selection of highly fluorescent MOLM-13 L149 tTA clones 
Selection of highly fluorescent clones would give clones of cells optimal for in vivo 
visualization due to high protein expression. The fluorescence properties of MOLM-13 L149 
tTA colonies were screened by fluorescence microscopy and brightest clones subsequently 
selected. When selected clones reached numbers of 0.5 x 106, they were further evaluated for 
GFP and NTR properties on FACS. Cells were prepared as described in Section 3.4.1. 
 
3.4.3.2 Selection of highly bioluminescent MOLM-13 L192 tTA clones in Time-domain 
Small Molecular Imager (TD-SAMI) 
Similarly, selection was performed to find cell-clones with a high, stable expression of 
luciferase. However, as luciferase is a bioluminescent reporter, selection could not be 
performed by FACS, and the clones were therefore screened using TD-SAMI. 
 
Approximately 100 000 cells of each clone were counted and diluted in complete medium to a 
total volume of 150 µl, and transferred to individual wells on a 96-well plate. A control with 
wild type MOLM-13 cells was prepared using the same procedure. Luciferin (1.6 µg/µl) was 
added each well 10 min prior to imaging. The 96-well plate was placed on the table in the 
imager. Using the eXplore Optix acquisition software, the region of interest were chosen and 
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plates were scanned with scan step 1.0 mm and integration time 0.6 s. By analysing the 
images using the Optix Optiview software, the clones with highest luciferase expression were 
selected and grown up. When at a sufficient concentration, these clones were further analysed 
using the same procedure as described above, however now with increasing amounts of cells; 
1.0 x 106, 0.5 x 106, 0.1 x 106, 0,05 x 106 and 0,01 x 106 cells of each clone, and the best three 
clones further grown up. 
 
3.5 Animal care 
3.5.1 General animal care 
The experiments were approved by The Norwegian Animal Research Authority and 
performed in accordance to The European Convention for the Protection of Vertebrates Used 
for Scientific Purposes. 
 
NOD/SCID IL2γnull mice were housed in groups of maximum five per individually ventilated 
cage (IVC-cage), bedding and cages were changed and autoclaved once every week. The 
environmental conditions were scheduled to provide 12 hours dark/light, temperature of 21°C 
and a relative humidity of 50 % (maximum fluctuation +/- 10%), in addition to continuously 
access to food and autoclaved water. The health status of the mice was monitored by 
observation and weight registration at least three times a week. Mice were placed under a heat 
lamp after procedures resulting in cooling of the body.  
 
3.5.2 Preparation of cells for intravenous injection 
Approximately 10 x 106 MOLM-13 cells were counted and spun down at 1500 rpm for 10 
minutes at 4°C, washed x1 in RPMI-1640 medium without FBS, before resuspended in 300 µl 
medium without FBS and transferred to 0.5 ml 28 G insulin syringe. Cells were injected in 
pre-irradiated mice within one hour.   
 
3.5.3 AML MOLM-13 L192 mouse model 
NOD/SCID IL2γnull mice were irradiated with a sub-lethal dose of 1.5 Gy (60 cGy/min) from 
a photon radiation source (BCC Dynarray CH4, 4 megavolt photon irradiation source) in the 
irradiation facilities at Haukeland University Hospital. Intravenous injection of leukemic cells 
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was performed within 4 hours of irradiation, 0.5 ml 28 G (gauge) insulin syringes were used 
for all injections. 
 
A metal device providing a chamber with an opening in the end, facilitating restraining of 
mice, and a plate behind the chamber with a stripe of opening facilitating light access from a 
light source underneath was used for restraining the mice for intravenous (i.v.) injection. Heat 
from the light underneath the plate led to dilatation of the tail vain in addition to contrast the 
vein from tissue, easing the procedure. The needle of the syringe was gently inserted to the 
vein, the syringe slightly moved from side to side to check that the needle was inside the vein, 
and the cells were injected slowly. Mice were carefully watched the first hour after injection. 
 
3.5.4 Intra-peritoneal (i.p.) injection  
I.p. injection was performed when administrating VPA and D-Luciferin. Mice were grasped 
by the fur/skin of the neck with forefinger and thumb, lifted, turned over in the palm of the 
hand and the tail was held with the fourth and fifth fingers to immobilize the mice. The mice 
were held at an angle with head slightly lower than the body, and slightly moved forth to let 
the organs slightly slide upwards, to avoid injuring the organs. A syringe cap with the tip cut 
off and a hole on the side was put on the syringe, to prevent too deep injection and to be able 
to see if the material was injected or leaked out. A very small, careful retraction was first 
performed to ensure a successful i.p. injection. If an air bubble was seen, material was slowly 
injected. If any other material was retracted, the syringe was removed and discarded, and a 
new attempt was done using a new syringe.  
 
3.5.5 Subcutaneous (s.c.) injection 
The skin of the neck was lifted in the same way as when grasping (the mice still standing), 
leaving a triangle of skin between the ears and above. The needle was inserted underneath the 
skin, and the material slowly injected. A resulting bump on the place of injection showed a 
successful s.c. injection. S.c. injection was used for injection of saline if the mice were 
dehydrated. 
 
Methods 
37 
 
3.5.6 Per oral (p.o.) administration 
This method was used for administration of nutlin-3. A stainless steel needle with a silicone 
tip was put on a pre-filled 0.5 ml insulin syringe. To compensate for the dead space in the 
needle, the accurate volume capacity of the needle was measured and equal volume added in 
the pre-filling of the syringe. This was only necessary the first time if using the same needle 
further. Mice were immobilized as described for i.p. injection, but in an almost vertical angle, 
slightly leaned backwards with head highest. The syringe was held vertically, the needle 
introduced to the rear of the mouth of the mice, inducing swallowing leading to readily 
entering of the needle into the oesophagus, and the material was slowly injected. Feeding 
amount was limited to 1% of body weight. 
 
3.5.7 Anaesthesia 
Under depilation and imaging, mice were kept under anaesthesia at levels of 1 % isoflurane, 
50 % O2 and 50% N2O. To avoid dehydration of eyes, an eye ointment (Simplex, Hydro 
Pharma) was applied. The mice were kept under a heating lamp and observed when 
recovering, and 0.1-0.3 ml saline was injected s.c. to compensate for water loss if anaesthesia 
lasted longer than 30 minutes.  
 
3.5.8 Imaging of mice in Time-domain small animal molecular imager (TD-SAMI) 
Depilation of mice was performed prior to imaging by shaving and application of a depilatory 
cream for approximately 2 minutes when under anaesthesia, before washed in lukewarm 
water. The mice were left to recover under a heat lamp, before put under anaesthesia and 
transferred to the stage in the TD-SAMI. The region of interest was encircled by using the 
eXplore Optix software and the scan details were set by choosing integration time and scan 
step, before the scan was started. Images were analyzed using the eXplore Optix Optiview 
software. 
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3.6 Evaluation of combinational treatment in vivo 
 
3.6.1 Preparation of nutlin-3 
Nutlin-3 was orally administered as a suspension, suspended in vehicle consisting of 2 % 
hydroxyproyl cellulose and 0.5 % tween 80 in sterile water, as described in the literature [52]. 
50 mg nutlin-3 was suspended in 2 ml vehicle to yield a concentration of 25 µg/µl. Each 
mouse received 200 µl b.i.d, equalling a dose of 200 mg/kg b.i.d.  
 
3.6.2 Preliminary toxicity 
For VPA preliminary toxicity, four NOD/SCID IL2γnull mice received 500 mg/kg B.I.D for 
five doses. For nutlin-3 preliminary toxicity, three NOD/SCID IL2γnull mice received 200 
mg/kg B.I.D for eight days. For preliminary toxicity of the combinational therapy, four 
NOD/SCID IL2γnull mice received nutlin-3 200 mg/kg orally b.i.d and VPA 200 mg/kg i.p. 
b.i.d for eight days. The mice were weighed once daily under treatment and at least two days 
after. They were in addition closely observed; signs of poor general conditions being roughed 
fur, hunched posture, and decreased activity levels and weight loss.  
 
3.6.3 Treatment of mice inoculated with leukemic cells 
20 NOD/SCID IL2γnull mice inoculated with MOLM-13 L192 were grouped into four groups 
receiving different treatment (see table 3.1). The mice were treated for 21 days or until any 
sign of toxicity, treatment was initiated five days after inoculation. Disease 
progression/treatment efficacy would be followed by optical imaging. 
Table 3.1 Overview of the treatment regimen given to the various groups. 
 Control 
(vehicle) 
VPA  
(200 mg/kg 
b.i.d [75]) 
Nutlin-3  
(200 mg/kg b.i.d 
[52]) 
VPA + Nutlin-3  
(200 mg/kg b.i.d + 200 mg/kg 
b.i.d 
Total 
Mice with 
reporter gene* 
n = 5 n = 5 n = 5 n = 5 n = 
20 
* NOD/SCID IL2γnull-mice injected i.v. with 10 x 106 MOLM-13 L192 cells 
 
3.6.4 Disease progression and euthanasia 
The health status of the leukemic mice was tightly observed; roughed fur, hunched posture, 
decreased activity level and weight loss being used as signs of poor general conditions. The 
endpoint at which the mice were sacrificed was defined as weight loss of 15-20 % from initial 
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weight and lethargy. Euthanasia was performed by cervical dislocation in accordance to 
institutional guidelines [109].  
 
3.7 Statistics 
For statistical analysis of difference between treatment groups in vitro and in vivo, Student’s t-
test was used. To ensure no statistical significant difference in weights between the animals in 
the treatment groups, a one-way analysis of variance (ANOVA) was performed. The Grubbs 
outlier test was used for investigating outliers. For all statistical analysis, p < 0.05 was 
considered statistically significant. 
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4 Results 
 
4.1 Evaluation of efficacy of the combinational therapy of nutlin-3 and 
VPA in the MOLM-13 AML cell line 
To evaluate the efficacy of the combination of VPA and nutlin-3 in AML cells expressing wt 
p53, MOLM-13 wt cells were treated with various concentrations of the two drugs both alone 
and in combination over different time periods. Three assays were used for detection of 
cytotoxicity; DNA specific staining with Hoechst 33342, the colorimetric oxidation-reduction 
Alamar Blue assay and the bioluminescent ATP assay (Fig. 4.1). All assays are described in 
methods (Section 3.2). Controls were treated with equal amounts of vehicles used to dissolve 
the drugs, DMSO and saline for nutlin-3 and VPA respectively.  
 
 
 
Figure 4.1 MOLM-13 wt cells treated with VPA and nutlin-3 in combination. (A) Apoptosis in MOLM-13 
wt cells treated with nutlin-3 (0.5 - 10 µM) or VPA (50 - 1000 µM) alone and in combination over 24 (i), 48 (ii) 
and 72 (iii) hours (n=3). Nutlin-3 was added for the last 24 hours. Apoptotic and normal Hoechst 33342 stained 
nuclei were and percent normal nuclei of control calculated to find percentage viability. Controls were set to 100 
%. Extrapolation to find IC50 of nutlin-3 is exemplified in (ii). (B) MOLM-13 wt cells were treated with 5.0 µM 
nutlin-3 and 500 µM VPA alone and in combination, apoptosis detected by Hoechst 33342 after 24, 48 and 72 
hours (n=9), % viability was calculated as in (A). Control at each time point was set to 100 %. (C) Viability of 
MOLM-13 wt cells after 24 hours treatment with nutlin-3 (2.5, 5.0 or 10.0 µM) or VPA (250, 500 or 1000 µM) 
alone and combinations of nutlin-3 (2.5, 5.0 or 10.0 µM) + VPA (250, 250 or 500 µM) as assessed by Alamar 
Blue assay. Percentage viability calculated of control, with control set to 100 % (n=3). (D) Viability of MOLM-
13 wt cells treated with 5 µM nutlin-3 and 500 µM VPA both alone and in combination after 48 hours as 
compared to control, assessed by ATP assay (n=3). Percentage viability calculated of control, with control set to 
100 %. Error bars represent standard deviation. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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4.1.1 Apoptosis in MOLM-13 wt cells treated with combination of nutlin-3 and VPA 
assessed by Hoechst 33342 
A dose-response study of the combinational therapy of nutlin-3 and VPA was performed in 
MOLM-13 wt cells expressing wt p53. A series of different concentrations of VPA (50-1000 
µM) and nutlin-3 (0.5-10.0 µM), both alone and in combination were evaluated over three 
time points: 24, 48 and 72 hours (Fig. 4.1A). The combinations evaluated were all at ratios of 
1:100 between nutlin-3 and VPA. Induction of apoptosis by VPA alone was limited for all 
time points, but most prevalent at high concentrations (500 and 1000 µM) and after 
considerable time (72 hours). Nutlin-3 mediated apoptosis induction increased as a function of 
concentration and time with an effect detected as early as 24 hours. The combinations of 
nutlin-3 and VPA had the highest apoptosis inducing effect on MOLM-13 wt cells, which 
increased with incremental time and concentration. IC50 values were found by extrapolation  
(as exemplified in Fig. 4.1A(ii) after 48 hours) with IC50 values for nutlin-3 found to be 
approximately 8.8, 7.3 and 7.6 µM at 24, 48 and 72 hours, respectively. VPA never induced 
more apoptosis than 16 % of control. 
 
Three studies with treatment of MOLM-13 wt cells with nutlin-3 5µM and VPA 500 µM both 
alone and in combination were performed, results presented in Fig. 4.1B, lower panel. VPA 
alone showed limited apoptosis inducing effect. Nutlin-3 consistently induced apoptosis at all 
time periods. Combination showed highest apoptotic inducing effect, which increased up to 
48 and 72 hours. The effect of the combination was found significantly different from control 
and each of nutlin-3 and VPA alone, with p < 0.0001 in all cases. 
 
4.1.2 Viability in MOLM-13 wt cells treated with combination of nutlin-3 and VPA 
assessed by Alamar Blue assay 
Evaluation of treatment efficacy was also done by the colorimetric Alamar Blue assay. The 
assay provides a measure of cell viability as the non-fluorescent dye resazurin is reduced by 
mitochondrial and cytosolic enzymes in viable cells to the highly fluorescent resorufin. 
Nutlin-3 (2.5-10.0 µM), VPA (250-1000 µM) and nutlin-3 (2.5-10.0 µM) + VPA (250-1000 
µM) was added to the cells, viability detected after 24 hours and results presented in Fig. 
4.1C. VPA alone showed some limited degree of reduction of viability, reduction slightly 
increasing with higher concentrations. Nutlin-3 showed a significant increasing cytotoxic 
effect with increasing concentration (p < 0.01 for all concentrations as compared to control). 
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All three combinations showed similar significance to control (p < 0.01). The combination 
with 250 µM VPA and 5 µM nutlin-3 showed a significant difference to 5 µM nutlin-3 alone 
(p < 0.0001); however increasing VPA dose to 500 µM did not show a significant difference 
to 5 µM nutlin-3 alone. 
 
4.1.3 Evaluation of viability by ATP assay 
The ATP assay utilizes bioluminescent measurement of cellular ATP levels in order to detect 
viable cells. The assay was used to measure the effect of 500 µM VPA and 5.0 µM nutlin-3 
alone and in combination, viability measured after 48 hours, results presented in Fig. 4.1D. 
All treatments showed significant reduced viability compared to control, combination was 
significantly different from both VPA (p < 0.001) and nutlin-3 (p < 0.05). Thus, the 
preliminary results from all three assays suggested that the combination of nutlin-3 and VPA 
cooperated resulting in greater apoptosis, and possibly synergism. 
 
4.1.4 Investigation of synergism using Bliss Independence 
The increased effect of the combination versus each drug alone was closer investigated for 
synergism, calculated using Bliss Independence. From the response to each of the drugs alone 
at specific concentrations, the expected response to the combination at similar concentrations 
may be calculated, using equation 3.1 (Section 3.2.4). A positive difference between real 
response and expected response is then ascribed to synergy. Difference between real cytotoxic 
response and expected cytotoxic response to the different concentrations assessed by Hoechst 
33342 (from Fig. 4.1A), increased with increasing doses with largest difference at 5 µM 
nutlin-3 and 500 µM VPA, before decreasing for 10.0 µM nutlin-3 and 1000 µM VPA (not 
shown). This shows that to best utilize the synergistic effect, the combination of 5 µM nutlin-
3 and 500 µM VPA should be used. 
  
Difference in response calculated from Hoechst 33342 assay with nine replicates (Fig. 4.1B), 
Alamar Blue assay (Fig.4.1C) and ATP assay (Fig.4.1D) are presented in Fig 4.2, showing a 
difference between real and expected response for the combination in all assays and after all 
time points studied. Largest difference was found after 72 hours with Hoechst assay, an 
excess response of 0.56 ascribed to synergism. A higher synergistic response was found using 
the Hoechst assay compared to Alamar Blue after 24 hours, similarly compared to ATP assay 
after 48 hours.  
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Figure 4.2 Bliss Independence results. (A) Bliss results from Hoechst 33342 assay from the response to nutlin-
3 (5.0 µM) and VPA (500 µM) both alone and in combination over 24, 48 and 72 hours. Nutlin-3 always added 
the last 24 hours. (B) Bliss results from Alamar blue and ATP assay at similar concentrations as in (A).Alamar 
blue assay was performed after 24 hours, ATP assay after 48 hours (including 24 hours pre-incubation with 
VPA). A positive difference between real response and fractional response is ascribed to synergy Error bars 
represents standard deviation.  
 
Synergism of the combination was detected by three assays with distinct end points as regards 
cell viability, and it was desirable to investigate if these promising results were translatable in 
vivo. It was thus desirable to evaluate these drug combinations in an in vivo model of MOLM-
13 induced AML, and to evaluate the effect employing optical imaging. Thus, MOLM-13 
cells were thus transfected with constructs containing fluorescent (green fluorescent protein 
(GFP) and fluorescence inducing nitroreductase; L149) or bioluminescent (firefly luciferase; 
L192) proteins in order to develop and establish an imageable MOLM-13 AML xenograft 
model for evaluation of the combinational therapy.   
 
4.2 Establishing an imageable in vivo xenograft model of MOLM-13 AML  
The combination of nutlin-3 and VPA was found to show a synergistic effect assessed with 
three different assays in vitro (Section 4.1). It was therefore desirable to take the therapeutic 
strategy into an in vivo AML model for further evaluation of the combinational therapy with 
evaluation of efficacy performed using optical imaging. MOLM-13 wt cells were therefore 
transfected with the construct L149 (expressing NTR and GFP) or L192 (expressing 
luciferase) in order to develop and establish such an imageable AML model. 
 
4.2.1 Transfection of MOLM-13 wt cells with GFP and NTR expressing L149 tTA  
Several attempts were made in order to transfect of MOLM-13 wt cells with the L149 tTA 
construct as described in methods (Section 3.3). When virus supernatant and protamine 
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sulphate was directly added to MOLM-13 cells, no live cell population was obtained.  
However, following the protocol including VSV-G pseudotyped virus, concentration of virus 
supernatant and spin infection (Section 3.3.2 and 3.3.4) live cell colonies were obtained. 
Based on previous experience in our lab, a large variation in protein expression among the 
cells was to be expected. Thus, thorough selection of live cells aided by a selection agent was 
performed, additionally to subsequent sorting and further selection using FACS in order to 
optimize protein expression of the cells.  
 
4.2.2 Selection of MOLM-13 L149 tTA cells with Puromycin 
The puromycin resistant gene included in the L149 vector (Fig. 2.1) allows puromycin 
selection of successfully transfected cells from wild type cells. Thus, the MOLM-13 L149 
clone obtained was treated with the antibiotic puromycin as described in methods (Section 
3.3.5). A resulting live population indicated successful antibiotic selection. However, as 
observed by fluorescence microscopy, the surviving cells showed variable expression of the 
proteins of interest; GFP and NTR. Hence, to obtain more viable clones and to further 
optimize expression of high levels of proteins of interest, cells were sorted by FACS (Section 
4.2.3).  
 
4.2.3 Sorting of MOLM-13 L149 cells by FACS 
In an attempt to obtain viable MOLM-13 L149 clones with high fluorescent protein 
expression, sorting by FACS was performed as described in methods (Section 3.4.3). FSC and 
SSC showed a large variation in viability within the clone (not shown), confirming the afore-
mentioned observation from fluorescence microscopy. Additionally, variable GFP 
fluorescence intensity was observed, in contrast to more uniform NTR-CytoCy5S 
fluorescence intensity. The cells were gated for live population and thereafter for the top 10 % 
levels of both fluorescence intensities. Single cells were sorted into five 96-well plates. After 
approximately two weeks incubation, viable clones were found in about 10 % of the wells. 
These were further grown to allow selection of sub-clones expressing highest levels of 
fluorescent proteins of interest by FACS. 
 
4.2.4 Selection of highly fluorescent MOLM-13 L149 clones 
Identification of GFP and NTR-CytoCy5S fluorescent properties in the resulting MOLM-13 
L149 clones was performed by FACS to enable selection of highly fluorescent clones, 
selection performed as described in methods (Section 3.4.3.1). A rough selection of clones 
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with high levels of GFP and NTR-CytoCy5S fluorescence was performed by screening using 
fluorescence microscopy, exemplified in Fig. 4.3 (upper right corner in A and B). Seventeen 
clones were found to show sufficient intensity of both GFP and NTR-CytoCy5S fluorescence, 
and thus selected to be further evaluated by FACS for quantification of fluorescence intensity, 
as exemplified in Fig. 4.3. 
 
Fluorescence intensities revealed by FACS were very variable for all seventeen clones and 
overall lower than obtained with other cell lines transfected with the L149 construct in our 
lab. Signal to noise ratio (S/N) gives a measure of fluorescence intensity of e.g. a clone 
(signal) as compared to background (noise). The clone found to show highest levels of both 
fluorescence intensities compared to background is presented in Fig. 4.3, with S/N ratios of 
13.5 for GFP and 24 for NTR-CytoCy5S. From previous experience we know that S/N ratios 
necessary for successful in vivo imaging required S/N ratios of 350 for GFP and over 100 for 
NTR-CytoCy5S [110]. The MOLM-13 L149 clone was therefore considered not bright 
enough for use in vivo, and bioluminescence was contemplated as a valuable alternative. 
Hence, bioluminescent MOLM-13 cells were engineered. 
 
 
 
Figure 4.3 MOLM-13 wt cells transfected with the L149 construct. (A) GFP fluorescence intensity (green) as 
assessed by FACS in comparison to MOLM-13 wt (blue) and fluorescence assessed by fluorescence microscopy 
(upper right corner). (B) NTR-CutoCy5S fluorescence intensity (red) assessed by FACS in comparison to 
MOLM-13 wt incubated with CytoCy5S (1µM) (blue) and fluorescence assessed by fluorescence microscopy 
(upper right corner).  (C) Intensity of GFP and NTR-CytoCy5S fluorescence of MOLM-13 L149 (red) compared 
to MOLM-13 wt (blue) incubated with CytoCy5S (1µM). Signal to noise (S/N) ratio of median fluorescence 
intensity (MFI) represented as bar chart in corner. Microscopy images are 20x magnification. 
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4.2.5 Transfection and puromycin selection of MOLM-13 wt cells with luciferase 
expressing L192 tTA  
Similarly to transfection of MOLM-13 cells with the L149 tTA construct, several attempts 
were made in order to transfect of MOLM-13 wt cells with the L192 tTA construct (Fig. 2.1B 
and C). Transfection using protocol including concentration of VSV-G pseudotyped virus and 
spin infection (Section 3.3.2 and 3.3.4) eventually resulted in a viable clone. As the L192 
vector also contains a puromycin resistant gene (Fig. 2.1B), antibiotic selection was 
performed similarly to the MOLM-13 L149 cells (Section 4.2.2). The resulting live 
population indicated selection of MOLM-13 L192 cells from wild type cells. The cells were 
then grown and sorted by FACS in order to obtain viable MOLM-13 L192 clones.  
 
4.2.6 Sorting of MOLM-13 L192 cells by FACS 
MOLM-13 L192 cells were sorted by FACS solely on basis of viability as described in 
methods (Section 3.4.3). FSC and SSC showed variations within the clone (not shown), and 
the cells were gated for live population (as compared to healthy MOLM-13 wt cells). Single 
cells were then sorted into five 96-well plates. After approximately two weeks incubation, 
viable cells were detected in around 50 of the wells. These were further carefully observed 
and grown and after approximately two weeks, sub-clones expressing highest levels of protein 
of interest were selected using TD-SAMI. 
 
4.2.7 Selection of highly bioluminescent MOLM-13 L192 clones by optical imaging 
To select the clones expressing highest levels of bioluminescence, the resulting clones from 
FACS sorting were evaluated by TD-SAMI as described in methods (Section 3.4.3.2). 10 x 
106 cells of forty-seven clones were evaluated. Variable bioluminescence was observed, and 
based on highest photon counts, five clones were selected for further evaluation (data not 
shown). The resulting five clones were further grown and after one week evaluated by TD-
SAMI (Fig. 4.4A). Clone 4 and 5 showed highest photon intensities and were expanded 
further. Clone 4 was selected to be used and evaluated in vivo to develop an AML MOLM-13 
imageable model and to detect disease development (Section 4.2.9).  
 
4.2.8 Sorting of MOLM-13 L192 clone 4 by FACS 
In order to investigate if further optimization of bioluminescent properties of the MOLM-13 
L192 clone 4 was possible, this clone was sorted again. After approximately two weeks of 
incubation, colonies of live cells were detected in 1 % of the wells, i.e. five clones. These 
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resulting clones were carefully expanded and bioluminescent properties were investigated by 
TD-SAMI similarly to the original clone 4. All clones showed similar or higher 
bioluminescent properties compared to the parent clone (not shown). All clones were then 
further grown for selection of brightest clone, results presented in Fig. 4.4C. Clone 3 of the 
original clone 4 showed maximum photon count 1.71 times that of the original clone 4, and 
total intensity 1.95 times that of the original clone 4. (Fig. 4.4D). This clone was expanded 
and grown for development of a bioluminescence in vivo imageable model of MOLM-13 
AML.  
 
 
 
Figure 4.4 Selection of highly bioluminescent MOLM-13 L192 clones. (A) Image presents bioluminescent 
properties of transfected MOLM-13 L192 cells, limit of detection found to be 10 000 cells. (B) Total photon 
counts of each clone from (A), average background subtracted. (C) Clone 4 from (A) was further subcloned by 
sorting by FACS. (D) Total photon counts from (C), average background subtracted. The cells were prepared as 
described in methods (Section 3.3.3.2), imaging performed ten minutes after luciferin (1.6 µg/µl) addition. 
Controls are 100 000 MOLM-13 wt. Background on images was set to 11.4, the average of all controls. Zero on 
scale bar equals to 11.4 photons/sec/mm2. 
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4.2.9 Establishing a bioluminescent MOLM-13 AML xenograft model  
Establishing an imageable AML mouse model was a requirement to enable in vivo therapy 
evaluation using optical imaging. The MOLM-13 L192 cell line was selected to be used for 
such a model. Two NOD/SCID IL2γnull mice were injected i.v. with 10 x 106 MOLM-13 L192 
cells as described in methods (Section 3.5.3) and imaged on day 7, day 10, day 14 and then 
every second day until sacrificed. Imaging was performed using a TD-SAMI drawing a region 
of interest and integration time set to 1.0 or 0.3 seconds (see legend Fig. 4.5) and scan step of 
1.0 mm was chosen. Background signal was found by injecting luciferin (150 mg/kg) i.p. in a 
healthy NOD/SCID IL2γnull mouse, the average of three measurements of each side was the 
set as background noise, and set as cut-off when analyzing the images. 
 
Results from bioluminescent imaging are presented in Fig.4.5A, exemplified by one mouse. 
The xenografted mice showed very similar pattern of disease development. Bioluminescence 
could already be detected from the lungs after two hours. After one week, engraftment of 
MOLM-13 L192 cells was detected with bioluminescent signals from locations consistent 
with the spleen and the brain, indicating leukemic infiltrates in the respective areas. From day 
10, additional signals were obtained from a location consistent with the spine, indicating 
leukemic infiltration of the spine. From day 16, distinct concentrated bioluminescent signals 
could be detected on various locations, e.g. on right shoulder of the mouse in Fig. 4.5A after 
22 days, dorsal view, and left side of the neck, ventral view after 20 days. These 
bioluminescent spots indicated leukemic infiltration of lymph nodes. From approximately day 
16, a bioluminescent signal from the abdominal area indicated leukemic infiltration of the GI-
tract, signal from this area drastically increased until the animals were sacrificed. From day 
20, massive bioluminescent signalling was detected in the area from the knees and to the 
brain, complicating localization of the signal, however, indicating a widespread leukemic 
infiltration throughout the body. 
 
Disease burden, represented by total photon counts, drastically increased from day sixteen 
until sacrificed as regards both dorsal and ventral side as exemplified in Fig. 4.5B (inset bar 
chart) for the mouse from Fig. 4.5A. Total photon counts for both sides summarized over time 
are presented in Fig. 4.5B, and were on day 25 approximately 27 times the counts on day 
sixteen. Sacrifice was performed after weight losses of 15-20 % and signs of clinical un-
wellness as hunched posture and decreased activity level were observed, average survival 
being 24 days. Diarrhoea was observed the day of sacrificing. 
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Figure 4.5 Development of an imageable AML MOLM-13 model. (A) Example of NOD/SCID IL2γnull mouse 
injected with 10 x 106 MOLM-13 L192 cells, imaging was performed after two hours, seven days, ten days, 
fourteen days and the every second day until sacrificed. Integration time was set to 1.0 second in all images until 
day eighteen, when bioluminescent signal was drastically increased and integration time was set to 0.3 seconds. 
Background was found to be 16.7 and 19.3 photons/mm2/sec for dorsal and ventral view, respectively. Images 
were normalized for integration time and photon counts converted to a log scale; zero on scale bar represents 
background for the respective views. (B) Total photon counts for the mouse in (A) were calculated for both 
dorsal and ventral view (left corner) and summarized over time. (C) Liver, spleen, lymph nodes, femur, lungs 
and GI-tract was dissected out and imaged. All organs showed bioluminescent signal, apart from femur. 
Appendix and upper part of the large intestine showed highest bioluminescence intensity (blue arrow). (D) Photo 
comparing appendix and upper part of the large intestine of healthy mouse and MOLM-13 xenografted mouse on 
day of sacrificing. Histochemistry was performed on lymph node, small and large intestine of the diseased 
mouse. Infiltration in small and large intestines was confirmed by histochemistry, infiltrated lymph node used as 
positive control (verified by Dr. Lars Helgeland, Gades Institute, Dept. of pathology, Haukeland University 
Hospital). All histochemistry was performed by Edith Fick, Gades Insitute. Microscopy images are 10x and 40x 
magnification. 
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To better identify where the bioluminescent signals arose from and confirm interpretation 
from whole body images, dissection and imaging of organs such as liver, spleen, lungs, 
gastro-intestinal tract (GI-tract), femur and lymph nodes was performed following necropsy 
(Fig. 4.5C), following whole body imaging. Imaging of the organs revealed bioluminescence 
from liver, spleen, lymph nodes and interestingly, very high intensity from the GI-tract, 
especially the appendix and upper part of the large intestine.  
 
Upon dissection a distinct enlargement of this area of the GI-tract was found in all MOLM-13 
L192 xenografted mice, shown in Fig. 4.5D (upper left images). The interesting finding of 
high intensity bioluminescence from the GI-tract and the above-mentioned enlargement was 
desirable to further investigate. Thus, to confirm infiltration of these parts, samples of GI-tract 
and lymph nodes were taken for histochemistry (Fig. 4.5D) and analysed by light microscopy. 
Histochemistry confirmed infiltrations of leukemic cells in lymph nodes. The lymph nodes 
were thus used as positive controls confirming infiltration in the wall of the small intestine 
and the large intestine. 
 
 
4.3 Evaluation of preliminary toxicity of nutlin-3 and VPA alone and in 
combination 
To determine how the two drugs VPA and nutlin-3 alone and in combination were tolerated 
by NOD/SCID IL2γnull mice, a pilot preliminary toxicity study was performed in healthy 
NOD/SCID IL2γnull mice. The mice were carefully monitored every day by monitoring of 
weights, observation of activity levels and overall behaviour. Additionally, mice were 
examined for dehydration and changes in fur.  
 
Three NOD/SCID IL2γnull mice received n-3 200 mg/kg orally b.i.d for eight days. After two 
days, a decrease in weight of 2.40 ± 1.37 g was observed, before weights stabilized (Fig. 
4.6A). Such initial weight loss by day 2 was observed for all mice receiving oral dosing, also 
mice only receiving vehicle, and was therefore ascribed to the stress of handling from oral 
administration and vehicle. One mouse died unexpectedly, showing no signs of clinical 
toxicity and cause of death was not identified. From this study, 200 mg/kg b.i.d of nutlin-3 
was considered a tolerable does for NOD/SCID IL2γnull mice.  
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Acute toxicity of VPA was investigated for doses of 500 mg/kg b.i.d for five doses, four 
NOD/SCID IL2γnull mice were dosed i.p. b.i.d, weights presented in Fig. 4.6B. One mouse 
died on day one, cause of death was identified likely to be puncture of the large intestine on 
i.p. injection, due to observation of swollen abdomen. The remaining mice lost 2.88 ± 0.99 g 
of body weight by day four. Thereafter, mice gained weight and stabilized around original 
weight after day six. No acute severe toxicity was observed apart from weight loss, however 
ataxia was observed in all, followed by sedation approximately ten minutes after 
administration. 
 
In order to investigate preclinical toxicity of the combination of VPA and nutlin-3, four 
NOD/SCID IL2γnull were given 200 mg/kg nutlin-3 orally b.i.d and 200 mg/kg VPA i.p. b.i.d, 
weights presented in Fig. 4.6C. On day 2, reduction in weights of 2.87 ± 0.94 g was observed. 
However, in contrast to earlier observations with stabilization in weights after day 2, a further 
decrease of 4.36 ± 0.98 g of original weight was observed on day 3. Additionally, ruffled fur, 
some reduction in activity levels and some degree of ataxia was observed for all four mice. 
Together, these observations lead to termination of toxicity study on day 3. Mice were 
monitored repeatedly until two weeks after last dose, when all four mice had recovered and 
regained original weight, and the fur was back to normal.  
 
To address a more tolerable combination, one NOD/SCID IL2γnull mouse received nutlin-3 
200 mg/kg b.i.d combined with decreasing doses of VPA from 200 mg/kg b.i.d to 100 mg/kg 
b.i.d to finally 50 mg/kg b.i.d, weight curve presented in Fig. 4.6D. After three days with 
nutlin-3 200 mg/kg b.i.d and VPA 200 mg/kg b.i.d, a weight loss of 15.6 % was observed 
additionally to ruffled fur and ataxia. After three doses of 200 mg/kg b.i.d nutlin-3 and 100 
mg/kg b.i.d VPA a weight loss of 15.8 % from original weight was monitored additionally to 
ruffled fur and ataxia. Reducing VPA dose to 50 mg/kg b.i.d no ataxia was observed. After 
three days of this regimen body weight was decreased by a total of 21.6 % of original body 
weight. After two days pause in treatment and an increase in weight, nutlin-3 200 mg/kg b.i.d 
and 50 mg/kg b.i.d VPA was dosed for four days. A weight loss was observed and thus 
treatment was stopped.  
 
To be able to see the effect of nutlin-3 200 mg/kg b.i.d and VPA 50 mg/kg b.i.d without 
possible influence from earlier dosing, two NOD/SCID IL2γnull mice received this dosage 
Results 
53 
 
regimen over a period of nine days, weight curves presented in Fig. 4.6E. On day two, a 
weight loss of 3.30  ± 0.19 g was monitored, followed by stabilization until day five, where 
overall weight loss was 3.37 ± 1.10 g From day 5 to day 6, a drop in weights was observed, 
overall weight loss on day 6 being 5.3 ± 1.17 g. Thus, VPA was withdrawn for two days due 
to weight loss and soreness after i.p. injections. Weights were subsequently stabilized. During 
treatment, no ataxia was observed, and fur was less ruffled than compared to regimen with 
higher doses of VPA, as 100 mg/kg b.i.d and 200 mg/kg b.i.d.  
 
From these studies dosing regimen for therapy evaluation in vivo was decided to be nutlin-3 
200 mg/kg b.i.d and VPA 50 mg/kg b.i.d for five days, then only nutlin-3 200 mg/kg b.i.d for 
two days to recover from soreness from i.p. injections and stabilize in weight. This regimen 
would be followed for 21 days. 
 
 
Figure 4.6 Weight curves for preclinical toxicity of nutlin-3 and VPA. (A) Three NOD/SCID IL2γnull 
received nutlin-3 (200mg/kg b.i.d); one mouse died unexpectedly on day six, treatment was stopped on day eight 
for the remaining mice. (B) Four NOD/SCID IL2γnull received five doses of VPA (500 mg/kg b.i.d). One mouse 
died on day one and was excluded from weight graph. (C) Four NOD/SCID IL2γnull were given nutlin-3 (200 
mg/kg b.i.d) combined with VPA (200 mg/kg b.i.d). Treatment was ceased on day 3 and the mice were left to 
recover. On day 16, all four had recovered in weight. (D) One NOD/SCID IL2γnull received nutlin-3 (200 mg/kg 
b.i.d) combined with decreasing doses of VPA from 200 mg/kg to 50 mg/kg as follows; 200 mg/kg b.i.d nutlin-3 
+ 200 mg/kg b.i.d VPA (day 0-3), 200 mg/kg b.i.d nutlin-3 + 100 mg/kg b.i.d VPA (day 8-10), 200 mg /kg b.i.d 
nutlin-3 + 50 mg/kg b.i.d VPA (day 10-12, and day 14-16), black arrows showing VPA intervention. No 
administration was performed on the days in between. (E) Two NOD/SCID IL2γnull mice received the dosage 
regimen of nutlin-3 (200 mg/kg b.i.d) and VPA (50 mg/kg b.i.d) for six days. Day 0 on graphs represents first 
day of treatment.  
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4.4 Evaluation of combinational therapy efficacy of nutlin-3 and VPA in a 
xenograft MOLM-13 AML model using optical imaging 
To evaluate the p53 activating combinational therapy in vivo, 20 NOD/SCID IL2γnull mice 
were i.v. inoculated with 10 x 106 MOLM-13 L192 cells and divided into four groups based 
on weights, gender and cage. A one-way analysis of variance (ANOVA) performed on the 
weight within groups showed no significant difference between any of the groups (p = 0.74). 
The mice were then equally distributed as regards cage and gender. Quantification of 
leukemic burden could be performed by bioluminescent imaging, hence therapy efficacy was 
evaluated by optical imaging as described in methods (Section 3.5.8), in addition to overall 
survival. Based on the preliminary toxicity data, therapy regimen was reduced from original 
regimen of nutlin-3 (200 mg/kg b.i.d) and VPA (200 mg/kg b.i.d) (Section 3.6.3), to nutlin-
3 (200 mg/kg b.i.d) and VPA (50 mg/kg b.i.d) for five days, then two days cessation of VPA, 
before starting on original regimen again. Treatment was scheduled to three weeks; regimen is 
presented in Table 4.1, exemplified by one week.  
 
         Table 4.1 Treatment schedule 
 
 
 
Day 
 
Vehicle 
(n = 5) 
 
VPA 
(50mg/kg b.i.d)
(n = 5) 
 
Nutlin-3 
(200 mg/kg b.i.d)
(n = 5) 
VPA + Nutlin-3 
(50 mg/kg + 200 mg/kg) b.i.d
(n = 5) 
VPA* Nutlin-3** VPA Nutlin-3 
1 + + + + + + 
2 + + + + + + 
3 + + + + + + 
4 + + + + + + 
5 + + + + + + 
6 - + - + - + 
7 - + - + - + 
         * = Saline, ** = 2 % hydroxypropylcellulose and 0.5 % tween 80 in sterile water 
         Plus indicates treatment, minus indicates no treatment 
 
Inoculation was performed on day 0, therapeutic intervention at day 3. The mice were treated 
for five days, then for two days only nutlin-3 was administered, following schedule. 
Intervention in therapy was done on basis of observations of signs of clinical un-wellness, 
decreased activity levels and weights. The animals were carefully observed and weighed 
every day; weights are presented in Fig. 4.7A. Dosing regimen was followed until day 12, 
nine days after treatment started.  On day 13 a weight loss of between 15-20 % of original 
weight was then observed in four of five mice in each of the nutlin-3 and the combination 
groups. Thus, treatment was ceased on day 13 and 14. An increase in weights was observed 
during the two non-dosing days; hence treatment was started again on day 15, twelve days 
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after start of treatment. On day 17, fourteen days after therapeutic intervention, a further 
weight loss was observed for the nutlin-3 and combination group and treatment was regarded 
as showing unacceptable toxicity and subsequently stopped one week prior to schedule.  
 
Imaging was performed (n = 4 per group) on day 7 and thereafter every week as long as 
animals survived, results presented in Fig. 4.7B and C. Bioluminescence was detected in all 
groups one week after inoculation and three days after therapeutic intervention, total photon 
counts significantly lower in combination group compared to control group (p < 0.05) as the 
only group showing significant difference (Fig. 4.7C). After two weeks and three weeks, 
bioluminescence still showed a lower total photon count in combination group as compared to 
controls, however not statistically significant. Neither the VPA group nor the nutlin-3 group 
were statistically significantly different from control in total photon counts at any time point.  
After four weeks, surviving animals were imaged; one VPA animal, two in each of the nutlin-
3 group and the combination group. 
 
As anaesthesia of each mouse in the first two weeks lasted for longer than 30 minutes, all 
animals received 0.3 ml saline s.c. to compensate for water loss. When developing disease, 
the animals were weaker and less anaesthesia was required to anaesthetise the animals. Hence, 
the mice were very carefully watched when going into anaesthesia and doses of isoflurane 
adjusted if needed. After imaging, when recovering from the anaesthesia, the animals were 
closely observed until fully recovered and given 0.3 ml saline s.c. When clinical signs of 
disease was observed, such as dehydration and reduced activity level, food was hydrated and 
put in the cages to ease access to food and water. Additionally, the mice received 0.1-0.3 ml 
saline s.c. every day. Euthanization was performed when moribund. A defined end point was 
difficult to set, as the disease developed very rapidly the last days. Therefore, animals were 
observed twice daily when diseased, to ensure that no animal suffered unnecessarily, and to 
ensure that all animals were euthanized at same stage in the disease. Animals were euthanized 
when showing signs of hunched posture, low activity level and a sudden drop in weight 
indicating that the animal did not take in food.  
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Figure 4.7 Evaluation of combinational therapy. (A) Weight curve of treatment groups showing average 
weight, standard deviation is left out for simplicity. Treatment was started on day 1, ceased on day 10, restarted 
on day 12 and terminated on day 14. (B) Imaging exemplified by dorsal view of one mouse from each treatment 
group, the mouse most representative for each group was chosen. Integration time was set to 1.0 second on week 
one and week two, and reduced to 0.3 seconds on week three due to increased bioluminescent signalling. Images 
were normalized for integration time and photon counts converted to a log scale; zero on scale bar represents 
background for dorsal view (Section 4.2.9). (C) Total photon counts from dorsal and ventral imaging after 7 
days, 14 days, 21 days and 28 days. On day 28, one VPA mouse was imaged and two from each of the nutlin-3 
and combination group. Error bars represents standard deviation, * = p < 0.05. (D) Survival data presented in 
Kaplan-Meyer curve.  
 
 
Survival data, presented in Fig. 4.7D, showed a significant increase in survival for all 
treatment groups as compared to control (p = 0.023 for VPA, p = 0.0019 for both nutlin-3 and 
combination group). Average survival was 24, 28, 30 and 29 days for the control, VPA, 
nutlin-3 and combination group, respectively. The animal surviving longest belonged to the 
combination group.  
 
These valuable in vivo results clearly suggest that the combination of nutlin-3 and VPA 
should be closer investigated in future studies.  
 
Discussion 
57 
 
5 Discussion 
 
AML is an aggressive disease characterized by several genetic mutations or rearrangements. 
Mutations in the pivotal tumour suppressor p53, however, are considerably rare in AML as 
compared to human cancer in general. Despite the low frequency of p53 mutations in AML, 
some of the various genetic defects characterizing AML may provide suppression of p53 
activity, e.g. overexpression of MDM2 and aberrantly recruited HDACs. Exploiting the low 
frequency of p53 mutation in AML, we postulated that a combination of a MDM2 inhibitor 
and a HDAC inhibitor would present a non-genotoxic p53 activation strategy utilising the 
wild type status of p53, potentially showing anti-leukemic effect and providing an alternative 
to the current standard therapy. Moreover, combining two drugs giving similar outcome but 
aiming different targets may provide non-overlapping side effects, thereby allow reduction in 
doses of each drug, and thus possibly reduce side effects. Additionally, combining two active 
compounds may reduce the risk of development of resistance mechanisms to either of the 
single agents, presenting a rationale for use of combinational therapy regimens.  As the main 
proportion of the AML patients are elderly tending to show low tolerance to the current 
standard therapy, such a combinatorial non-genotoxic alternative would be of great value. In 
this interest, the work in this thesis has been pilot studies as a proof-of-principle, and the 
promising results should be further investigated on all levels, both in vitro and in vivo.  
 
5.1 Evaluation of efficacy of the combination of nutlin-3 and VPA in the 
MOLM-13 cell line 
The efficacy of nutlin-3 and VPA both alone and in combination was evaluated in the AML 
cell line MOLM-13 expressing wt p53 using three different assays; the Hoechst 33342, the 
Alamar blue and the ATP assay. 
 
Assessed by Hoechst 33342, we found that nutlin-3 induced apoptosis in MOLM-13 cells 
expressing wt p53, conferring with the results found by Vassilev et al. [52] for wt p53 
expressing cancer cell lines. Moreover, cytotoxic effect found after 24 hours incubation with 
racemic nutlin-3 was between the expected effects shown for nutlin-3a and nutlin-3b [43], 
corresponding to the fact that we used a racemic mixture of nutlin-3. VPA (after 24 hours) did 
not show any significant effect in concentrations in the micromolar range assessed by Hoechst 
33342, consistent with the fact that the IC50 for inhibition of class I and II HDACs by VPA 
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lies in the millimolar range [73]. Moreover, as seen from Fig. 4.1A, VPA effect increased 
with time and concentration. This trend would possibly continue as described by Kawagoe et 
al. [70] for various human leukaemia cell lines. Incubation of VPA for 5 days here showed 
IC50 for almost all leukemic cell lines tested at concentrations between 0.3-1.8 millimolar, 
cytotoxic effect increasing with increasing concentrations for all. Furthermore, we found that 
the combination of nutlin-3 and VPA showed a higher cytotoxic effect in combination than 
each drug alone. This result is consistent with the fact that the two compounds both activate 
the p53 pathway; nutlin-3 by inhibiting the main negative regulator of p53, MDM2 [52], 
additionally to inhibiting MDM2-dependent deacetylation of p53 by HDAC1 [59]. VPA 
activates p53 by inhibiting class I and class II HDACs [62] known to deacetylate p53 [58]. An 
interesting observation was that the combination of nutlin-3 (5.0 µM) and VPA (500 µM) 
seemed to show higher cytotoxic effect than nutlin-3 (10 µM) after 48 and 72 hours, the 
difference was however not statistically significant. 
 
As VPA did not show any significant effect in the apoptosis detecting assay Hoechst33342, a 
viability assay measuring metabolic activity was used. Any decrease in metabolic activity 
subsequent of e.g. cell cycle arrest would possibly be detected in such an assay. VPA is 
known to induce apoptosis either at higher concentration or over longer time [70], however 
may induce cell cycle arrest prior to apoptosis. VPA showed no significant reduction in 
metabolic activity after 24 hour assessed by Alamar blue. The Alamar blue assay showed, 
however, higher sensitivity to nutlin-3 (2.5, 5.0 and 10.0 µM) than Hoechst 33342, possibly 
due to induction of cell cycle arrest, as shown by Kojima et al. [43] where nutlin-3a induced 
cell cycle arrest in MOLM-13 cells after 12 hours.  The combination of nutlin-3 and VPA 
showed an increase in cytotoxic effect compared to the two drugs alone for the three 
combinations investigated. The combinations of nutlin-3 (2.5 and 5.0 µM) and VPA (250 
µM) showed statistically significant difference to nutlin-3 alone at the respective doses.  
 
The ATP assay is another viability assay utilizing ATP as end point. To further investigate the 
effect of the combination with 24 hours pre-incubation of VPA prior to nutlin-3, the ATP 
assay was performed after 48 hours incubation of VPA. A reduction in viability caused by 
VPA alone not detected by Hoechst 33342 was detected by the ATP assay (Fig. 4.1D), and 
may suggest a differentiation effect by VPA after 48 hours causing a senescence type of state 
where the ATP endpoint fails to differentiate between cell death and senescence. The cells are 
probably moving towards apoptosis, shown by our own results from Hoechst 33342 after 72 
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hours (Fig. 4.1A(iii)) and as described by Kawagoe et al. [70]. Similar to the Alamar blue 
assay, the ATP assay showed a higher sensitivity to nutlin-3 (5.0 µM) treatment than assessed 
by Hoechst 33342, possibly due to the above mentioned nutlin-3 induced cell cycle arrest also 
detected by the Alamar blue assay. The ATP assay showed a similar response to the 
combination of nutlin-3 (5.0 µM) and VPA (500 µM) after 48 hours compared to Hoechst 
33342 results at same concentrations and time points. The observations from this assay may 
indicate that the differentiation effect of VPA induces sensitivity to nutlin-3. 
 
Valuable information about the efficacy of nutlin-3 and VPA alone and in combination were 
obtained by using the three different assays. Possibly, the ATP and the Alamar blue assays 
should be used at all the same time points as Hoechst 33342, to possibly yield more 
information about the cell status prior to induction of apoptosis.   
 
All assays suggested a synergistic effect of the combination of nutlin-3 and VPA calculated 
by Bliss Independence (Section 4.1.4). Largest effect ascribed to synergy was found for the 
combination of 5 µM nutlin-3 and 500 µM VPA (72 hours incubation), assessed by Hoechst 
33342. Alamar blue showed lower synergistic effect than Hoechst 33342 after 24 hours, 
possibly due to lower sensitivity to the combination and higher sensitivity to nutlin-3 alone, 
thereby yielding a higher expected response to the combination. The ATP assay showed lower 
synergistic effect than Hoechst 33342 after 48 hours, possibly due to its higher sensitivity to 
VPA, also yielding a higher expected response to the combination. However, despite the 
mentioned differences in sensitivity, all three assays showed a synergistic effect of the 
combination of VPA and nutlin-3, a promising result for this combinational strategy. 
 
The Bliss Independence method for calculation of synergy depends on non-interference 
between the agents investigated [103]. VPA and nutlin-3 have very distinct molecular targets; 
VPA targets HDACs whereas nutlin-3 very specifically targets MDM2. Based on these 
known mechanisms, we assumed non-interference between VPA and nutlin-3, and the Bliss 
independence method was therefore used to investigate synergism. However, the combination 
has not been probed adequately enough to establish non-interference, and mechanisms behind 
synergy should be further investigated e.g. by experiments discussed in the next paragraph. If 
the drugs would be found to interfere with each other, an alternative method for calculation of 
synergy not dependent on this non-interference should be performed, e.g. with obtaining 
detailed dose-response curves and use of the Chou and Talalay method [103]. A reason for a 
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possible interference would be the MDM2-HDAC1 complex, whereby inhibition of MDM2 
possibly inhibits HDAC1 mediated deacetylation of p53. However, despite of synergistic 
effect of a combination, several reasons mentioned above implicate rationale for use of 
combination in therapy in vivo. In our study, it is obvious that both in vitro and in vivo studies 
show an increased anti-leukemic effect with combination compared to either drug alone. Our 
results thereby imply the combination as a valuable non-genotoxic strategy in AML treatment. 
 
As previously mentioned, AML is a disease characterized by a differentiation block in the 
myeloid progenitor lineage [7] and differentiation inducing therapy has shown promising 
effects by increasing susceptibility of AML cells to drug induced-apoptosis [19]. ATRA 
induced differentiation in treatment of APL is an example of such, sensitizing APL cells for 
additional chemotherapy [16, 19]. Additionally, compared to normal cells, tumour cells are 
more prone to trigger an apoptotic response if the mechanism for evading apoptosis is 
repaired [111]. Subsequently, this will lead to selective apoptotic response of tumour cells, as 
specifically proven for MDM2 inhibition, where tumour cells have been shown to respond by 
undergoing apoptosis whereas normal cells undergo cell cycle arrest [49]. These mechanisms 
are promising for apoptotic inducing anti-cancer drugs, and may, in addition to the 
overexpression of MDM2 in AML, be an explanation for the higher nutlin-3 sensitivity of 
AML cells versus normal haematopoietic cells [43]. A possible mechanism behind the 
synergy would be that VPA increases the sensitivity of the cell to nutlin-3, as the combination 
showed higher effect the longer VPA had been applied prior to nutlin-3. The differentiating 
effect and restoration of the balance between pro- and anti-apoptotic members of the Bcl-2 
family of VPA [112] may lead to matured cells more sensitive to active p53, the latter 
increasing in response to MDM2-inhibition by nutlin-3. Such change in levels of pro- and 
anti-apoptotic proteins in the Bcl-2 family could be further investigated, by e.g. Western 
blotting of untreated cells compared to VPA treated cells over different time points and 
compare with combinational treatment at similar time points. An additional interesting future 
experiment would be to investigate and compare the levels of p53 and acetylated p53 before 
and after treatment of the single agents nutlin-3 and VPA and in combination with pre-
incubation of VPA over different time points, by e.g. Western blot. Nutlin-3 has additionally 
proven to induce maturation of AML cells itself [45], leading to additional differentiation and 
possibly terminal differentiation of AML cells, both through p53 activity but also in a p53-
independent manner [45]. This p53 independent differentiation inducing effect of nutlin-3 
may implicate a therapeutic value also in AML cases with mutated p53. Another interesting 
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future experiment could be to investigate and compare the differentiation effect of the drugs 
alone and in combination, by e.g. using flow cytometry and conjugated antibodies specific for 
differentiation markers of myeloid progenitors, such as CD11b/c and CD14.   
 
 
5.2 Establishment of an imageable in vivo xenograft model of MOLM-13  
5.2.1 Transfection of MOLM-13 wt cells with the GFP and NTR expressing L149 tTA 
and the luciferase expressing L192 tTA  
MOLM-13 L149 cells (expressing GFP and NTR) and MOLM-13 L192 cells (expressing 
firefly luciferase) were successfully developed. The transfection process was found to be 
somewhat challenging, as the protocol initially followed did not give successfully transfected 
live cell clones. Following a protocol including VSV-G pseudotyped vectors, concentration of 
virus titre and spin infection, was however successful for both vectors. Retroviral vectors 
normally interact with host cells through glycoproteins in the viral envelope binding to 
specific cell surface receptors, different viruses therefore have defined host ranges 
determining transfection efficiency [113]. Introduction of envelope proteins from a different 
virus, e.g. VSV-G, to the initial vector gives a pseudotyped vector with the host range to that 
of the envelope protein donating virus [113]. VSV-G mediates viral entry to the cell by 
membrane fusion through unspecific interaction with a phospholipid component of the cell 
membrane instead of binding to specific cell surface receptors, thereby showing a very broad 
host range [113]. VSV-G-pseudotyped retroviral particles also tolerate to be 
ultracentrifugated, allowing concentration of the virus supernatant, increasing the efficiency 
of transfection [104, 113]. Higher infection efficiency has also been found by using spin 
infection, especially suspension cell types, like MOLM-13. Presumably, the centrifugation in 
some way sensitizes the cells to the retrovirus [104], possibly by increasing the proximity of 
the viruses to the cells and increase access to the cells. 
 
As can be seen from Fig. 2.1, both the L192 and L149 vector expresses a puromycin resistant 
gene, and the tTA vector expresses a streptomycin resistant gene, enabling antibiotic selection 
of transfected cells from wt cells. Previous experience in our lab had shown no distinct 
difference between selection results using both puromycin and streptomycin, or only 
puromycin. Thus, thorough selection was performed with only puromycin. As the puromycin 
resistant gene will only be expressed if the tTA vector is successfully expressed in the target 
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cells i.e. driving expression of L149 and L192, this would presumably select out only the cells 
transfected with both the tTA vector and L192 or L149 vector. Further, as seen from Fig. 2.1, 
the L149 vector contains a luciferase gene placed between the GFP and the NTR gene, and 
would therefore be assumed to be translated if NTR is translated. However, a surprising 
finding in our lab was that no functional luciferase protein was expressed in cells transfected 
with this construct, despite detection of both functional GFP and NTR. The reason for this is 
not known, and subsequently a different vector for luciferase had to be used, namely the L192 
vector. 
 
Single cell sorting of MOLM-13 L149 was performed using FACS. Gating of cells was 
performed on basis of viability and fluorescence properties, such that the sorted cells would 
be known to be in the top 10 % of the cells for expression of both GFP and NTR. To select 
out the clones with highest fluorescence properties, identification of protein expression of 
each successfully obtained clone was performed by flow cytometry. Upon selection of L149 
clones, a higher CytoCy5S fluorescence than GFP fluorescence was detected in all clones. 
Additionally, seen from Fig. 4.3 for the clone showing highest intensities of both fluorescence 
properties, a population with close to no GFP fluorescence and lower NTR-CytoCy5S 
fluorescence than the main clone was detected, which should be excluded. Further sorting by 
FACS gating for top 10 % levels of both fluorescence intensities would provide such 
optimisation of the clone. The MOLM-13 L149 cells showed sufficient fluorescent properties 
for use in vitro, however, comparing to previous experience in our lab with in vivo imaging 
using GFP and NTR (Section 4.2.4), the MOLM-13 L149 cells showed insufficient 
fluorescent properties to be used in vivo. Nevertheless, further optimisation of the clone as 
mentioned above may possibly give rise to brighter clones suitable for in vivo evaluation.   
 
The MOLM-13 L192 cells express the bioluminescence inducing enzyme, luciferase, and 
single cell sorting may therefore not be performed by FACS. However, as the flow cytometer 
allows identification of the viability of the cells within a clone, gating may be performed for 
the viable cells to exclude debris and pre-apoptotic cells. In this way viable MOLM-13 L192 
clones were obtained, which could further be evaluated for bioluminescent properties by TD-
SAMI. One of the clones obtained from this evaluation (clone 4, Fig.4.4A) was successfully 
used for development of an imageable MOLM-13 AML mouse model (Fig. 4.5A). The 
evaluation using TD-SAMI provides information of all cells in a well in total, in contrast to 
flow cytometry which allows information of fluorescent properties of each individual cell and 
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thereby the variation within a clone. Further optimisation of the clone 4 was indeed found 
when sub-cloning the parent clone (Fig. 4.4 C), suggesting a variation in bioluminescent 
properties of the cells within the original clone 4. The brightest of the sub-clones was 
successfully used for the MOLM-13 AML mouse model used in therapy evaluation. Possibly, 
sub-cloning of the brightest clone (clone 4.3) would subsequently give rise to clones with 
further increased bioluminescent properties.   
 
As mentioned, evaluation and subsequent selection of highly bioluminescent L192 clones was 
performed using TD-SAMI. The high concentration of cells (1.0 x 106 cells/150 µl) may limit 
the access to and thereby penetration of the cells by luciferin. Therefore, thorough mixing of 
luciferin and the cell suspension was performed prior to imaging, to ensure high levels of 
access to the cells for luciferin and subsequent penetration. It was also observed that the 
density at which the cells grew prior to imaging strongly influenced bioluminescent 
signalling, with cells growing at high density showing lower bioluminescence. This may 
possibly be due to cells entering a quiescent state at high concentrations, thereby not 
expressing as high levels of proteins as cells in a logarithmic growing phase. Hence, cells 
were carefully observed prior to selection, with all clones grown at similar density to enable 
high accuracy comparison between clones. 
 
5.2.2 Evaluation of MOLM-13 L192 cells in vivo 
NOD/SCID IL2γnull mice were successfully i.v. xenografted with MOLM-13 L192 cells. 
Previous results from MOLM-13 i.v. inoculation of NOD/SCID mice have shown variable 
engraftment and disease development, with average survival of 35-40 days, survival however 
showing a span from 16 to 60 days (E. McCormack, personal communication). Due to early 
development of thymic lymphoma, NOD/SCID mice show a relatively short life span (150 -
400 days) [114], which may complicate survival data when such variations in survival are 
shown as described above. The NOD/SCID IL2γnull strain of mice, however, do not develop 
thymic lymphoma and have a longer life expectancy (> 90 weeks) thereby reducing the risk of 
complicating survival data [86]. Additionally, our results show a consistent MOLM-13 
engraftment, with survival of 23-25 days after i.v. inoculation. These results suggest the 
NOD/SCID IL2γnull strain of mice as a more appropriate model for AML MOLM-13 
engraftment, due to low variation in both disease development and survival.    
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The disease developed after inoculation of 10 x 106 MOLM-13 L192 cells showed a disease 
with an acute end phase, like AML, with survival of 23-25 days post inoculation. Imaging 
visualized the aggressive development in the end phase of the disease (Fig. 4.5), with total 
photon counts drastically increasing from day 16 post inoculation until moribund. Infiltrations 
formed in the brain, spine, bone marrow (femur) and lymph nodes, all typical 
characterizations of AML [7, 8]. An interesting finding was the intensive bioluminescence 
from the abdominal area (Fig. 4.5A) indicating massive infiltration of the intestines, an 
indication verified by imaging of the intestines alone (Fig. 4.5C), additionally to the observed 
enlargement of appendix and colon (Fig. 4.5D), and the confirmation of results with 
histochemistry (Fig. 4.5D). The intestines are served with high blood supply due to uptake of 
nutrients, additionally to a high supply of lymph vessels, which might explain how the AML 
cells access and infiltrate these organs. Enlargement of appendix has previously been 
described as a rare occasion in leukaemia [115], however this part of the disease development 
should be further investigated. Observation of diarrhoea when moribund may reflect 
malignant changes in the intestines.  
 
Summarized, an imageable MOLM-13 AML xenograft model with a reproducible disease 
development was successfully established (Fig. 4.6). The model confirms the valuable use of 
bioluminescent reporter genes in optical imaging [87, 92, 95, 98]. The low background noise 
found (Section 4.3) agrees with the literature as regards bioluminescent imaging [87, 92], 
which, together with the absence of autoluminescence, made analyzing of images a relatively 
readily performed task. Moreover, results confirmed optical imaging as a valuable tool for 
disease monitoring of mice by non-invasively allowing detection of early disease and pattern 
of disease development, additionally to quantitative localization of disease [88]. The 
reproducible disease development was promising for detection of intervention point and for 
using the model for AML therapy evaluation.  
 
5.3 Evaluation of preliminary toxicity of nutlin-3 and VPA 
A pilot preliminary toxicity study of nutlin-3 and VPA was performed in order to address any 
adverse effect and to define a tolerable dose regimen. Doses of the nutlin-3 and VPA were 
based on literature, describing doses of both at 200 mg/kg b.i.d for 20-22 days as well-
tolerated in Nude mice and NOD/SCID mice, respectively [52, 75]. 
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Nutlin-3 was found to be well-tolerated at doses of 200 mg/kg b.i.d orally administrated for 
eight days (Section 4.4 and Fig. 4.6A), in accordance with the literature [52]. The initial 
weight loss most possibly reflects the stress of handling, as oral administration of mice is a 
challenging technique. VPA has been known to be a well-tolerated compound for decades, 
with a known, mild toxicity profile, with risks of severe toxicity increasing with increasing 
dose [12, 68, 69]. Doses of 300 mg/kg b.i.d has been described to show no toxicity in 
NOD/SCID mice [75]. Hence, acute toxicity of high dose VPA was investigated. If nutlin-3 in 
any way should potentiate the effect of VPA, subsequent potential acute side effects of VPA 
would by this be addressed. A weight loss was observed during treatment, which was 
regained rapidly after termination of treatment. Ataxia and sedation was observed during 
treatment, both effects reported as adverse effects of VPA [12].  
 
The initial combination regimen was based on previous results that nutlin-3 was well tolerated 
and reduced tumour size with 90 % in oral doses of 200 mg/kg b.i.d over 20 days [52] and 
VPA administered i.p. in doses of 200 mg/kg b.i.d was well tolerated and significantly 
reduced spleen weight of i.v-inoculated human leukemic cells [75]. The combination of the 
two doses, however, was not very well tolerated as indicated by weight loss (Fig. 4.6C).  
Reducing the VPA dose to 50 mg/kg gave a combination that was found to be tolerated over 
six days, followed by two days of cessation of VPA. The initial weight loss seen in Fig. 4.6E 
is most possible due to stress of handling, as weights stabilize after two days. 
 
When preparing the nutlin-3 suspension, it was found to be a very rapid settling suspension. 
Uniform dosing was therefore difficult to obtain, as the suspension did not remain sufficiently 
homogenous in the period between re-suspension and removal of amount required in the 
dosing syringe. The hydroxypropyl cellulose gave an increased viscosity, aiding some 
reduction in settling. Increasing the viscosity would further reduce settling, however not be 
preferable for the oral dosing, as such a suspension would be difficult to dose due to aspects 
regarding flow through the syringe and in the oesophagus of the mice. The challenge with the 
nutlin-3 suspension would possibly be overcome by using only the active enantiomer, nutlin-
3a [53], as only half the amount of the suspending agents hydroxypropyl cellulose and Tween 
80 (polysorbate 80) are used for this suspension [53], additionally only half the volume would 
be required for similar doses.  
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5.4 Pilot efficacy evaluation of the efficacy of the combinational therapy of 
nutlin-3 and VPA in a xenograft model of MOLM-13 AML monitored 
by optical imaging 
The combination of nutlin-3 (200 mg/kg b.i.d) and VPA (50 mg/kg b.i.d) significantly 
inhibited disease development seven days post-i.v. inoculation of MOLM-13 L192, after four 
days of continuous treatment, as the only group showing significant difference to control (Fig. 
4.7C). Disease burden was quantified by bioluminescent imaging. The trend shows lower total 
photon counts for the combination group at all time points, however not statistically 
significant after fourteen and twenty one days. A high difference between mean total photon 
counts of the combination group and the control group was however found after both fourteen 
days (at fourteen and twenty one days, respectively: combination; 27 685 ± 304 
photons/mm2/sec, control; 145 992 ± 71647 photons/mm2/sec) and twenty one days 
(combination; 210 023 ± 149 944 photons/mm2/sec, control; 987 482 ± 507 460 
photons/mm2/sec). These large differences in mean values imply that a higher number of 
animals per group, with the same deviations, would probably show statistical significance. 
Compared to the mean values of total photon counts for the VPA and the nutlin-3 groups after 
fourteen days (VPA; 29 775 ± 4348 photons/mm2/sec, nutlin-3; 54 295 ± 43140 
photons/mm2/sec) and twenty one days (VPA; 533 133 ± 232 204 photons/mm2/sec, nutlin-3; 
525 141 ± 374 467 photons/mm2/sec), the combination group also shows a significantly lower 
mean value. Considering the intervention in treatment after ten days of treatment and the early 
termination of treatment, the combination group still seems to show a lower disease burden 
implying that the combinational treatment delayed AML development, both compared to 
control and to treatment with either of the two drugs alone. From this therapy efficacy 
evaluation, bioluminescent non-invasive imaging was found a valuable tool for monitoring of 
anti-leukemic therapy efficacy, as previously described [96, 97]. The disease development 
was very similar in all mice, and followed the same pattern as described in section 4.3, all 
showing enlargement of appendix and caecum/upper part of colon.  
 
Survival data confirmed the trend observed from imaging, with a delay in disease 
development for all treatment groups (Fig 4.9D), as they all showed statistically significant 
increase in survival as compared to control. Highest significance was seen for the nutlin-3 and 
the combination group, showing same statistical difference. After the first four days of 
continuous treatment with combination, a break of VPA treatment for two days was 
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performed as scheduled. After this break, VPA was administered only four additional days, 
and not continuously. From our in vitro data (Fig. 4.1A) we found that the combination 
showed highest efficacy when VPA was continuously incubated over time. Thus, the 
observation that the nutlin-3 group and the combination group showed similar survival data 
may reflect the absence of continuous VPA administration during the treatment period, so that 
inhibition of disease the last two-three weeks in the combination group was mainly due to the 
effect of nutlin-3.  
 
An issue to consider when using bioluminescent imaging is the ATP-binding cassette (ABC) 
family transporter ABCG2/BCRP as described by Zhang et al. [116]. This membrane efflux 
pump was found to pump out D-luciferin from the cell and alter bioluminescence 
independently of expression of luciferase. The ABCG2/BCRP pump has been found to be 
expressed in a variety of malignancies, however rarely in AML [117]. Nevertheless, such a 
pump would provide a possible bias of bioluminescent imaging. However, as discussed 
above, survival data correlates well with imaging results obtained in our study, suggesting that 
bioluminiscent imaging data reflect the actual therapeutic effect for the agents tested in this 
study. Nevertheless, the possible presence of the ABCG2/BCRP pump in our model should be 
investigated, possibly by administrating an inhibitor of the pump, such as the calcium channel 
blocker nifedipine [116]. There may be other factors influencing the bioluminescent 
signalling in such in vivo therapy evaluation. For example, as seen from our in vitro results, a 
reduction in ATP levels after incubation of VPA was assessed by the bioluminescent ATP 
assay, possibly due to the differentiation inducing effect of VPA (discussed in Section 5.1). 
Such VPA induced differentiating effect on the MOLM-13 L192 cells may also reduce ATP 
levels in the in vivo study, leading to reduced bioluminescence. Therefore, it would be 
interesting to compare to the imaging results obtained using the bioluminescent model with a 
fluorescent xenograft model in vivo. 
 
Observations in the therapy study showed a lower tolerance for nutlin-3 200 mg/kg b.i.d 
(Section 4.5 and Fig. 4.7A) as in the preclinical toxicity study, for the same time period. 
Similarly, the combination of nutlin-3 (200 mg/kg b.i.d) and VPA (50 mg/kg b.i.d) was less 
tolerated in the therapy study compared to preclinical toxicity. A similar weight loss for mice 
treated with nutlin-3 alone and mice treated with combination was found in the therapy study, 
indicating that the toxic effect was caused by nutlin-3. As mentioned above, no toxicity of 
nutlin-3 has been reported, however mild haematopoietic abnormalities and slightly increased 
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apoptosis in the small intestines have been indentified for reduction in MDM2 levels [118, 
119], effects due to increased p53 activity. A possible reason for the difference in nutlin-3 
tolerance in the toxicity study and in the therapy study may be that the animals in the therapy 
study had been sub-lethally irradiated three days prior to treatment start. Such whole-body 
irradiation induces p53 activity and it has been shown that MDM2 protects mice from the 
lethal effects of irradiation [119], where a small reduction in MDM2 levels activated p53 and 
sensitized cells to radiation. In our case, MDM2 activity was inhibited three days post 
irradiation, and may thereby have inhibited the protective effect of MDM2 to the irradiation, 
hence showing increased toxicity compared to animals not subjected to irradiation. Hence, 
dosing regimen should possibly be adjusted for irradiated animals. 
 
As mentioned above, the bioluminescent imaging performed in this pilot study was found a 
valuable tool in evaluation of therapy efficacy, and expanded studies with higher numbers of 
animals should be performed to increase statistical relevance. However, one by one imaging 
of cohorts of mice for e.g. evaluation of therapy as performed in this study is time demanding. 
Whole body imaging of an average weight mouse imaged with scan step 1.0 mm and 
integration time 1.0 second, which was found necessary for early disease detection, takes 
approximately 30 minutes on each side. The scan step determines the area from which emitted 
light is detected over time. A scan step of 1.0 mm means that the region of interest chosen is 
divided into pixels of 1.0 mm2.The integration time determines the time period for detection 
of emitted light from each pixel. With an integration time of 1.0 seconds, emitted light from 
each pixel is detected for 1.0 second. The total time for one image is thus dependent on size of 
region of interest, scan step and integration time. The optical imaging system used in our 
project is a time-domain system designed for fluorescent imaging, but has been engineered to 
enable use also for bioluminescent imaging. In future studies of larger cohorts a different 
system designed for bioluminescent imaging could possibly be used. An example is the 
system used by Armstrong et al. [96] where bioluminescent whole body imaging of four mice 
simultaneously required two minutes.  Another alternative may be using the GFP and NTR 
reporter system. Whole body-imaging performed in our lab using these reporters allowed use 
of integration time of 0.2-0.3, reducing the time required to one third. For future in vivo 
therapy efficacy studies, this time reduction may favour the above mentioned optimising of 
the MOLM-13 L149 clones for use in vivo. An additional advantage of this reporter system is 
the opportunity to analyse organ samples, e.g. blood samples, by FACS, which is not possible 
with bioluminescent reporters. 
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As evaluated in our in vitro studies of nutlin-3 and VPA in combination (Section 4.1 and 5.1), 
VPA may induce nutlin-3 sensitivity over time, and should possibly be administered 
continuously. In our treatment regimen, VPA would just reach steady state (after five half 
lives, i.e. 3.1 days) before ceasing after five days. In our treatment study, VPA was then never 
allowed to reach steady state again. Therefore, a preliminary toxicity study should be 
performed, to identify a therapy regimen allowing continuously administration of VPA, 
possibly administered once daily to protect the abdomen of the mice from soreness resulting 
from i.p. injections. Moreover, in vitro results showed highest efficacy of combinational 
treatment when VPA was added prior to nutlin-3, efficacy increasing with time. This may 
indicate a benefit for administering a loading dose or pre-treatment of VPA prior to nutlin-3 
treatment, consistent with treatment regimen in the clinical trial in our department (Section 
1.1.3), where VPA is administered one and two weeks prior to ATRA and cytarabine, 
respectively. 
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5.5 Conclusion and future perspectives 
A pilot study of a novel AML therapy strategy has been performed by combining the MDM2 
inhibitor nutlin-3 with the HDAC inhibitor VPA. Nutlin-3 and VPA in combination showed 
synergy in vitro in an AML cell line expressing wild type p53 (MOLM-13), synergistic effect 
was detected by the three distinct viability assays; Hoechst 33342, ATP and Alamar blue. 
Furthermore, a reproducible imageable MOLM-13 AML xenograft model was established and 
successfully used for in vivo evaluation and translation of in vitro results of the combinational 
therapy of nutlin-3 and VPA. A pilot preliminary toxicity study showed that a combination of 
nutlin-3 at oral doses of 200 mg/kg b.i.d and VPA 50 mg/kg b.i.d administered i.p. for five 
days followed by two days of only nutlin-3 200 mg/kg b.i.d was well tolerated. Upon 
evaluation of the combinational therapeutic strategy in vivo in the bioluminescent MOLM-13 
AML model a significant inhibition of disease development was detected after one week. 
Limitations due to dosing regimen, however, prevented further evaluation of continuous 
therapy of VPA and nutlin-3. Nevertheless, despite the early cessation of treatment, all 
treatment groups showed a significant increase in survival compared to control, implicating 
non-genotoxic p53 activation as a successful aim in AML therapy. The results from this pilot 
study has shown a proof of principle, where the p53 activating concept of combining a 
MDM2 inhibitor and a HDAC inhibitor shows synergy in vitro and significant delay in AML 
disease development in vivo, and should therefore be further investigated as alternative in the 
treatment of AML. It should, however, be noted that, for such a p53 activating therapy, 
determination of p53 status of each individual patient would be a pre-requisite, as p53 
mutations may possibly provide resistance to such therapy. 
 
An interesting and valuable future approach would be investigation of the mechanism behind 
the synergistic effect constituted by nutlin-3 and VPA. One such approach could be to closer 
investigate the effects of nutlin-3 and VPA alone and combined on levels of p53 and 
acetylated p53, e.g. by Western blot analysis. The levels should be investigated before and 
after treatment, and over different time period for pre-incubation with VPA. Moreover, it 
would be interesting to investigate the effect of VPA on the balance of pre- and anti-apoptotic 
members of the Bcl-2 family over different time periods by Western blot analysis. Subsequent 
comparison with viability of cells treated with the combination including pre-incubation of 
VPA over the respective time periods would possibly provide information on how the effect 
of VPA on the Bcl-2 family correlates with the synergistic effect of the combination. 
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Investigation of the differentiation effect of each of the single drug compared with the drugs 
combined by using conjugated antibodies specific for differentiation markers and flow 
cytometry would be another interesting experiment for closer investigation of the synergistic 
effect of the combination. 
 
If the above mentioned experiments would reveal interference between nutlin-3 and VPA, 
further viability studies with more concentrations of each drug alone and in combination 
should be performed. Obtaining detailed dose-response curves would thereby enable 
investigation of synergy by methods not dependent on non-interference between the agents 
like the Bliss Independence method. Such a method could be the already mentioned Chou and 
Talalay method.  
 
As mentioned, the lower tolerance of nutlin-3 and combination treatment in the therapy study 
may be a consequence of the mice being subjected to irradiation prior to treatment. Therefore, 
a preliminary toxicity study should be performed taken into account the effect of irradiation. 
A maximal tolerated dose of nutlin-3 alone over time should be obtained, and subsequently an 
appropriate dosing regimen for the combination over time for mice subjected to sub-lethal 
irradiation. Further, to improve the nutlin-3 suspension properties, possibly the active 
enantiomer of nutlin-3, nutlin-3a, should be used. This would half the volume required for 
each dose and probably facilitate the oral dosing, subsequently reduce the exposition of 
handling for the mice. 
 
Our own in vitro results of the combination of nutlin-3 and VPA and the protocol used in the 
clinic at our department imply a pre-loading with VPA prior to nutlin-3 treatment, and should 
be investigated in vivo. VPA treatment should be initiated prior to nutlin-3 and administered 
continuously, whereas nutlin-3 should be investigated with both continuous and intermittent 
administration, in order to determine whether VPA sensitises the AML cells to nutlin-3 in 
vivo as shown in vitro. An intermittent administration of nutlin-3 would provide a dosing 
regimen easier to administrate and lower the stress of handling for the animals, additionally to 
lower the cost of the treatment.  
 
To obtain higher statistical relevance of the results from the in vivo therapy evaluation, an 
expanded study with increased number of animals should be performed. As mentioned, the 
bioluminescent imaging system successfully used in this study would possibly be inefficient 
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for a higher number of animals due to the image acquisition time required. The mentioned 
alternative of using a charge-coupled device system designed for bioluminescent imaging 
could be a possibility. This would however require resources at high cost and therefore be a 
distant future possibility. To utilize the resources already present in our lab, optimization of 
the GFP and NTR expressing MOLM-13 L149 clone would provide a valuable less time 
demanding alternative. Additionally, such a fluorescent model would provide the opportunity 
of analysing samples from mice by flow cytometry. It would also provide the interesting 
possibility to compare the fluorescent imaging to the bioluminescent imaging of this model. 
 
The promising results of combining a MDM2 inhibitor and a HDAC inhibitor should indeed 
be further investigated, possibly also by including other MDM2 inhibitors and HDAC 
inhibitors to search for easier administrable and more specific compounds, compared to 
nutlin-3 and VPA, respectively.  
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